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Figure 1.1 Immune system of vertebrates at a glance, showing the role of both immune systems in protecting the host against pathogens (adapted from
www.virtual medicalcentre.com).
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1 INTRODUCTION
Life originated on this planet roughly three billion years ago. The simple cell modified,
diversified and adapted various environmental changes and got scattered into various species
throughout this planet. Even though all living organisms behave and look differently, there are
some similarities. The basic defense mechanisms of all cellular organisms (plants, vertebrates,
invertebrates) are to protect their host against foreign invasions. The immune system comprises a
complex network of cells, tissues and organs co-operating to defend the body by discriminating
between self and non-self and neutralizing potentially harmful pathogens. The following
paragraphs will deal with the immune system in general particularly focusing on the vertebrate
(human) immune system (for summary see Figure 1.1).
1.1IMMUNE SYSTEM
Immune system comprises of a complex network of cells and organs, whose basic function is to
discriminate between self and invader (bacteria, fungi, viruses and other parasites) It protects
their host, by constantly monitoring the body for any pathogens and trying to neutralize these
potential threats by rapidly eliminating them [1]. However, these disease-causing agents have
developed their own strategies to avoid detection and elimination. To combat this, the immune
system developed mechanisms such as phagocytosis, release of antimicrobial peptides,
complement activation and other basic immune responses. These mechanisms, have evolved and
have been maintained from the primitive immune systems to the current immune system of the
vertebrates [2]. The evolution of the immune system is depicted in Figure 1.2. The typical
immune system in vertebrates is differentiated into Innate immunity and Adaptive immunity [3]
as shown in the overview of the immune system in Figure 1.1.
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Figure 1.2 Evolution of Immune system from invertebrates to vertebrates, showing the distinct milestones in
development (adapted from Beck, G. and Habicht, GS.[2]).
The immune system is mainly built up by cells of the hematopoietic system and particularly
depends on the white blood cells (WBC or leukocytes). Hematopoietic stem cells (HSCs) are
located in the bone-marrow differentiating into common myeloid progenitor cells (CMPs) and
common lymphoid progenitor cells (CLPs). The CMPs further differentiate into macrophages,
granulocytes, dendritic cells and megakaryocytes, while the CLPs give rise to B- and T-cells,
natural killer cells (NK), plasma cells and dendritic cells [4]. The hematopoiesis showing
development of different blood cells is shown in Figure 1.3.
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Figure 1.3 Hematopoieses, showing the development of different blood cells from hematopoietic stem cells (HSCs)
via different progenitors into mature cells, which is the pillar for immune-mediated responses. LT-HSC, long-term
repopulating HSC; ST-HSC, short-term repopulating HSC; MPP, multipotent progenitor; CMP, common myeloid
progenitor; CLP, common lymphoid progenitor; MEP, megakaryocyte/erythroid progenitor; GMP,
granulocyte−macrophage progenitor (adapted from Larsson J. [5]).
The Innate immune system is the first to elicit a combative response against most pathogens
before the adaptive immune system takes over. Thus in a way innate immunity triggers the
adaptive immunity as a response to infiltrations. Although the innate response is not pathogen-
specific, it buys the adaptive immune system enough time for their rather slow onset At times;
the adaptive system aids the innate system to eradicate infections. Thus, both innate and adaptive
immune systems must work as players of the same team to assure flawless host defense
mechanism as shown in Figure 1.4 [4].
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Figure 1.4 Co-operative efforts of the innate and adaptive immune systems, eliminating pathogens and
providing optimal host defence mechanism. Abbreviations: TH, T-helper cells; TReg, regulatory T-cells; IFN-γ
interferon-γ; IL, interleukin; TCR, T-cell receptor; TGF-β, transforming growth factor-β (adapted from Romani L. [4]).
1.1.1 INNATE IMMUNITY (NON-SPECIFIC IMMUNITY)
Innate immunity is the first line of defense and is found in all plants and animals. It is of
primitive origin and an antigen-independent response, which is, utilized by the host within min to
h after facing an inflammatory stimulus. In vertebrates, the primary responders of this branch of
the immune system are phagocytic cells (polymorphonuclear leukocytes (PMN), macrophages
(MΦ), monocytes), mast cells, eosinophils, basophils, and NK cells [3]. The phagocytes of the
vertebrate system are recognized as evolutionary descendants of phagocytic cells of primitive
origin [6], which ingest and kill microbes by producing numerous degradative toxins and clear
them from the body. Phagocytes recognize unique molecules, pathogen-associated molecular
patterns (PAMPs), shared by groups of related microbes, which are essential for their survival
but absent in host cells. These (PAMPs) are recognized by pattern recognition receptors (PRRs)
present in the host system, which is primarily responsible for the immediate response during
infectious inflammatory response [7]. Additionally, these cells also react to damage associated
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molecular pattern molecules (DAMPs), which are thought to be responsible for the initiation and
perpetuation of inflammatory responses and tissue repair under non-infectious (sterile)
conditions [8, 9]. DAMP proteins originate from extracellular sources, such as extracellular
matrix (e.g. hyaluronan and heparin sulphate) and are released at the site of inflammation,
affecting the function of antigen-presenting-cells (APCs) [10, 11]. Moreover, the cells secrete
structurally different endogenous molecules called “alarmins” that signal tissue and cell damage
[12, 13]. Alarmins function as potent effectors of the innate immune system along with alarming
the immune system by recruiting and activating the leukocytes that are capable of activating
antigen-presenting-cells [13]. The damaged cell around the injured/inflamed tissue undergoes
necrosis and releases cellular contents including DAMPs, as shown in Figure 1.5. Since alarmins
are released by degranulation or necrosis in response to tissue injury or inflammation, they are
considered to be a subset of DAMPs [14]. DAMPs activate the cells of the innate immune
system via toll-like-receptors (TLRs), which leads to an increase of cytokine and chemokine
production (IL-6, TNFα, MCP-1, IL-10). The cytokines and chemokines trigger and recruit
phagocytes like neutrophils, monocytes, macrophages and promote removal of debris, thereby
promoting tissue re-generation [15].
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Figure 1.5 Release of damage associated molecular pattern molecules (DAMPs), into extracellular space
secreted by inflammatory and necrotic cells. The DAMPs activate the target cells by signaling through various
receptors; receptor for glycation end products (RAGE), toll-like receptor 2 (TLR2) or TLR4, TLR7/8/9 co-operating
with toll ligands triggering an inflammatory response (adapted from Jaeschke H. [15]).
Innate immune system uses a number of receptors that respond to pathogens by recognizing
repeating patterns of carbohydrate or lipid moieties, which are unique for the microbial surfaces
[6]. The mannose receptor, for example, promote phagocytosis, while other secreted receptors
promote phagocytosis by opsonizing pathogens or by activating the complement system [3].
These pathogen recognizing receptors are key players in signaling-induced responses for local
inflammation, containment, the recruitment of new effector and the initiation of adaptive
immune system [3, 6]. The receptors mostly involved in transmitting such signals belongs to the
family of Toll-like receptors (TLR) which activates the host defense system, enabling the
initiation of the adaptive immune system [7]. The ligation of TLR-2, -4 activates the
transcription factor NFκB along with the induction of a number of genes for chemokines and co-
stimulatory molecules that are important in the course of adaptive immune response [3].
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1.1.2 ADAPTIVE IMMUNITY (SPECIFIC IMMUNITY)
Adaptive immunity, an antigen-specific immune response, is more complex than the innate
response and has evolved in early vertebrates [16]. The adaptive immune system constitutes the
second line of defense against invading pathogens and is triggered only if the are not efficiently
cleared by the innate immune response. The immune system encounters foreign substances and
with the help of the components of adaptive immune system, eliminates the specific antigen and
develops a memory for the specific antigen. During a consecutive infection, the antigen
responses maintained in memory cells, allow the host to quickly eliminate the pathogen. It takes
days for the adaptive immunity to respond after it encounters a new antigen, but it is capable of
clearing the infections more efficiently than the innate response [17]. The cells of the adaptive
immune system are lymphocytes- B-cells and T-cells. There are two major branches of adaptive
immunity: a) cell mediated immunity and b) humoral immunity.
a) CELL MEDIATED IMMUNE RESPONSE
Cell-mediated immunity is an immune response that involves the activation of macrophages and
natural killer (NK) cells, the production of antigen-specific cytotoxic T-lymphocytes and the
release of various cytokines in response to an invading pathogen. Naive T-lymphocytes (T-cells),
which are circulating in the blood and lymphatic tissues, are activated by binding to a specific
antigen present on the surface of APCs. APCs have the ability to modify these native T-
lymphocytes into effector T-cells, helper T-cells and cytotoxic T-cells. The helper T-cells (CD4+
T-cells) are the most important group of T-cells, which are involved in universal stimulation of
the immune system. When CD4+ T-cells come into contact with its specific antigen they secrete
cytokines, which aid in intensifying phagocytosis, and antibody production by B-cells and
cytotoxic T-cells. The activated cytotoxic T-lymphocytes recognize the cells carrying pathogen
epitopes and induce apoptosis. Activated macrophages and NK, clear the apoptotic cells and can
also cause de novo synthesis of cytokines that influences the functions of other cells in the host.
Memory T-cells are responsible for maintaining antigen responses during consecutive infections
[3, 6, 18].
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b) HUMORAL IMMUNE RESPONSE
Humoral immunity involves the production of antibody molecules in response to an antigen and
is mediated by B-lymphocytes (B-cells). Antibodies (immunoglobulins) are proteins that are
generated by somatic rearrangement in B-cells that bind to specific antigens on the pathogens
with high specificity and function as opsonins and markers for target destruction by phagocytes.
The B-cells are co-stimulated by CD4+ T-cells and these stimulated cells are capable of secreting
antibodies circulating in the blood. Upon coming in contact with the antigen, the B-cells
withdraw into the lymphoid tissue and divide rapidly, followed by the transformation into plasma
cells or memory B-cells. Plasma cells make antibodies to the antigen which circulate in the blood
and enter the tissue via inflammation. The antibodies, either by affinity maturation or by
modifications of the immunoglobulin chain called isotype switching, harbor the humoral immune
response. These accessory processes can activate complement system, phagocytosis or opsonin
promotion, aiding the immune system in detecting and eliminating microbes [19, 20].
Both cell mediated and humoral mediated responses are essential for host defense. Antibodies
generated from B-cells bind to the pathogens in blood and at mucosal surfaces thereby
preventing the spread of infection. Contrastingly, T-cells recognize and kill infected cells [3].
1.2CELLS INVOLVED IN THE IMMUNE RESPONSE
The immune response depends on the white blood cells which originate from the HSC located in
the bone marrow. The HSC differentiate into CMPs and CLPs [21]. CMPs are the precursors for
macrophages, granulocytes and other leukocytes of the innate immune system [22]. CLPs
differentiate into B-cells and T-cells. Both the progenitors can give rise to dendritic cells [22,
23]. The cells and cellular components involved in the innate immune response are introduced
briefly in the following sections.
1.2.1 MONOCYTES
Monocytes are derived from the bone marrow and enter the circulation upon maturation. They
remain as monocytes for about 3 days (human) and convert to either MΦ or dendritic cells
(DCs), as seen in Figure 1.4 [24]. Monocytes are well-equipped phagocytic cells, which play a
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vital role in homeostasis and infection and hold a prominent role in the interplay between innate
and adaptive immune system [25]. Monocytes are divided into a classical (CD14+CD16-) subset
and a non-classical (CD14lowCD16+) subset in humans, inflammatory (Ly6C hi) and resident
(Ly6C low) monocytes in mice, respectively [26]. Under inflammatory conditions, monocytes
are recruited from the bone marrow and differentiate into MΦ or DCs [27].
1.2.2 MACROPHAGES
MФ are aptly described as highly mobile mononuclear cells which have the highest level
of phagocytic activity. MФ develop from progenitor cells in the bone marrow as seen in
Figure 1.4. Monocytes entering the circulating system differentiate into tissue resident MФ
and DCs [28]. These cells play an important role in tissue homeostasis, tissue repair and in
clearance of toxic and apoptotic material [24]. A number of receptors are expressed on MФ,
that recognize foreign components e.g. lipoproteins and oxidized lipids. This receptor
repertoire includes for example mannose receptor, scavenger receptors, Toll-like-receptors,
and complement receptors. With the help of these receptors, macrophages mediate their
interactions with natural and altered-self components of the host as well as a range of
pathogens [29]. These receptors help in synthesizing bioreactive lipids and releasing
coagulation cascade components. They also help by secreting proteases, protease inhibitors,
cytokines and chemokines [30, 31]. Macrophages, based on their activation state are divided
into either classically activated (M1) or alternatively activated (M2) macrophages. M1
macrophages are those that are activated through Toll-like-receptors and interferon-γ, where
they exhibit increased secretion of cytokines and chemokines, enhanced killing of intracellular
microorganisms and increased expression of co-stimulatory molecules [32].  M2 macrophages
are those that are activated by IL-4, IL-13, IL-1 or vitamin D3 leading to secretion of IL-10
and expressing mannose receptor and arginase-1 [33].
1.2.3 LYMPHOCYTES
Lymphocytes are activated during inflammation but in less numbers compared to monocytes and
MФ. They give rise to two lineages in the hematopoietic differentiation; smaller lymphocytes (T-
cells and B-Cells) and larger ones (NK-cells) [3]. NK cells are a part of the innate immune
system and have three major tasks: 1) they distinguish infected cells by recognizing the change
of major histocompatibility complex (MHC) molecules on the surface, 2) they respond to
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cytokines and interferons released in the circulatory system, and 3) they get activated and release
cytotoxic granules to destroy the pathogen. T-cells and B-cells are parts of adaptive immune
system with T cells primarily involved in cell mediated immunity and B cells in humoral
immunity [6, 7, 34].
1.2.4 DENDRITIC CELLS
Dendritic cells (DCs) are special cells which develop either through the lymphoid or myeloid
pathways, as shown in Figure 1.4. They possess high antigen-processing and -presenting
capacity, are highly phagocytic, and present among circulating cells in the blood. Furthermore,
DCs are also responsible for regulating lymphoid responses in steady state and during infection.
A specific section of dendritic cells called plasmacytoid DCs (pDCs) live longer than other DCs
subsets in circulation and surprisingly resemble B-cells due to their lymphoblast-like appearance
under steady state conditions and their ability to rearrange immunoglobulin H diversity-joining
genes. These cells are specialized in responding to viral infiltrations, producing large amounts of
Type I interferons [35-37].
1.2.5 NEUTROPHILS
Neutrophils are white blood cells that form a major part of the innate-immune response, which
are found in the circulation. Neutrophils are released into the blood stream from the bone marrow
[38]. They mature from HSCs and are released into circulation, as shown in Figure 1.4.
Neutrophils play a key role in immunity, range between 40-70% in peripheral blood of humans
found at concentrations of 3-5*106 cells/ml. The concentration of neutrophils increases manifold
during infection. Neutrophils are terminally differentiated cells with short life span but survive
for a couple of days, once they migrate into the tissues [39-41]. Contrastingly, mice show around
25% PMN in peripheral blood with the life span ranging 11-13 h [42, 43].
PMN are the first line of defense against invading microorganisms. Appearance  of neutrophils at
the site of infection or injury is a hallmark of inflammatory response [44]. The bone marrow is
the place exclusively for granulopoiesis to occur under inflammation. Neutrophils are profoundly
mobilized into the circulatory system and cleared rapidly from the blood stream [45]. The
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myeloid specific growth factors granulocyte colony-stimulating factor (G-CSF) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) play important roles in the maturation process
of PMN. The PMN precursors undergo five divisions from myeloblasts through promyelocytes
to neutrophilic myelocytes. The primary granules are formed in the promyelocyte stage and
secondary granules are formed in myelocytic stage. In the later stages of neutrophil maturation,
metamyelocytes, band forms and segmented cells are formed. Teritiary granules are produced at
the metamyelocyte stage. Secretory vesicles are likely formed by endocytosis during circulation
of PMN in blood [46, 47].
1.2.5.1 Neutrophil granule proteins
Granule proteins are crucial effectors in the PMN immune response [48]. These PMN-derived
proteins allow efficient phagocytosis and exert direct antimicrobial activity [49]. These proteins
activate macrophages [49] and monocytes [50], allowing enhanced pathogen clearance. As
mentioned in the previous section, three kinds of granule subsets are present along with secretory
vesicles [51]. Many proteins are stored in these granule subsets and the PMN releases them in an
orderly fashion on its way to the inflammatory site, as shown in Figure. 1.6.
 Primary granules (azurophilic granules) are the first granules formed during PMN
differentiation. The proteins present within the granules aid in killing and digestion of
ingested particles inside the cell. These granules are the storage centers of all cellular
myeloperoxidase (MPO) and other cytotoxic and bactericidal mediators [52]. They
contain large amounts of lysosomal enzymes and are used against phagocytosed microbes
in the inflamed tissues. Due to their affinity to azure dyes, they are called azurophilic
granules. The primary granules mainly contain cationic proteins (defensins, serine
proteases) and proteolytic enzymes that kill bacteria, they break down bacterial cell walls
there by proving toxic to pathogens [53, 54]. The typical markers for primary granules
are defensins and MPO [52, 55].
 Secondary granules (specific granules) are formed when the granulocytes lose their
azurophilic staining properties and hence are stained by both acidic and basic dyes in
myelocyte stage. These granules are also peroxidase negative granules which are unique
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for neutrophils and identified by their matrix content of lactoferrin and vitamin B12-
binding protein [56, 57]. Secondary granules are also named adhesomes as they contain
four types of extracellular matrix receptors: laminin, fibronectin, vitronectin and receptor
for C3b/fibrinogen. These granules contain NADPH-oxidase involved in the production
of reactive oxygen species (ROS) [55, 58].
 Tertiary granules (gelatinase granules) are peroxidase-negative, gelatinase-rich granules
containing proteins for adhesion, diapedesis, signaling and acidification. Furthermore,
they contain matrix metalloproteases (MMPs) that degrade extracellular matrix proteins
important for extravasation. Tertiary and secondary granules have some similar
components but in different amounts [46, 55].
 Secretory vesicles (phosphasomes) are recognized morphologically using albumin as
matrix marker and alkaline phosphatase as membrane marker. Alkaline phosphatase is
present on the inner side of the vesicle. These contain the integrins and receptors for
CD14, CD16 and formyl-peptide receptors. Secretory vesicles also contain plasma
proteins and azurocidin (also called heparin binding proteins (HBP)), which are essential
in extravasation and increased vascular permeability [53, 55].
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Figure.1.6 Orderly release of granule subsets at different stages of PMN extravasation, Release of secretory
vesicles following PMN adhesion leads to the deposition of azurocidin and proteinase-3 on the endothelial cell
surface and incorporation of receptors (CD14, CD16, β2-integrins) into the PMN cell surface. Transmigrating PMN
release tertiary granules, which contain proteases to help penetration of the basement membrane. The migrated
PMN deposit antimicrobial polypeptides (e.g. LL37, azurocidin, HNPs) and proteases (e.g. cathepsin G, elastase) in
the extravascular tissue, leading to interaction with nearby cells. Abbreviations: FPR, formyl peptide receptor; HNP,
human neutrophil peptide; MMP-9, matrix metalloproteinase 9; MPO, myeloperoxidase; TNF-R, tumor necrosis factor
receptor (adapted from Soehnlein,O. [50]).
1.2.5.2 PMN granule proteins of interest
a) Neutrophil elastase
Neutrophil elastase (NE), belongs to chymotrypsin-like serine protease superfamily [59]. It is
one of the most destructive enzymes that is present in the human body [59]. NE is stored in
azurophilic granules of PMN and is secreted along with reactive oxygen species (ROS), cationic
peptides and eicosanoids after an inflammatory stimulation [59, 60]. Furthermore, NE plays an
important role in host defense and in destruction of microorganisms [61], due to its potent
antimicrobial activity particularly against Gram-negative bacteria and fungi [62]. NE binds to
purified integrins, it shows a structural homology with other azurophilic granules and also forms
a major component of NETs [63, 64]. NE is exteriorized at sites of inflammation and has the
ability to degrade every component of extracellular matrix [65], including elastin, type I-IV
collagens, fibronectin, laminin and proteoglycans [59, 60]. The biological role of NE is to act as
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a secretagogue for cytokines, mucin, glycosaminoglycans [66], and alarmins, which allures other
immune cells leading to an immune response [64, 67].
Table 1 PMN granule composition
Constituents Primary
Granules
Secondary
Granules
Teritiary
Granules
Antimicrobial Myeloperoxidase
Lysozyme
Defensins
Lysozyme
Lactoferrin
Neutral proteniases Elastase
Cathepsin G
Collagenase
Complement-
activator
Gelatinase
Plasminogen-
activator
Acid hydrolases Proteinase 3
Cathepsin B
Cathepsin D
β-D-
Glucuronidase
α-Mannosidase
Phospholipase A2
Phospholipase A2
Cytoplasmic membrane
receptors
CR3, CR4
FMLP
Laminin
Others Chondroitin-4-
sulphate
Histaminase
Monocyte-
chemotactic
factor,
Vitamin B12
binding protein
Cytochrome b558
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b) L37/CRAMP
LL37, the sole human cathelicidin, is a 37 residue peptide sequence starting with two leucine
residues at the N terminal. Cathelin-related antimicrobial peptide (CRAMP) is the homologue
molecule of LL37 in mice showing very similar functions as its human counterpart [68]. It is
found in leukocytes (PMN, monocytes, mast cells), testis, bone marrow, sweat, wound-fluid,
squamous epithelia as well as some other tissues [69]. LL37 is generated from the proprotein
hCAP-18, encoded by the cathelicidin antimicrobial peptide (CAMP) gene. The proprotein is
stored in PMN and epithelial cells, after exicision from the signal peptide and is activated by the
cleavage of proteinase-3 leading to shorter peptides derived from LL37 [70]. In addition, the
other proteases, such as cathepsin and elastase in PMN, cleave LL37 in vitro [71].
LL37 plays an important role in neutrophil-mediated killing mechanisms, particularly in the
innate immune system [72]. It preferentially binds to negatively charged microbial membranes
and in a similar way it binds to negatively charged DNA. LL37-DNA interaction influences
transport of both immunomodulatory and antimicrobial effects [70, 73]. Self-DNA binding to
LL37 forms aggregated condensed structures that promote DNA translocation into the endocytic
pathway of pDC via Toll-like-receptor-9. It loses innate self-DNA tolerance and draws a rapid
induction of Type I interferon that initiate an immune response [74].
LL37 has broad antimicrobial property against Gram-positive and Gram-negative bacteria. The
levels of LL37 increases after injury and the blocking of LL37 by antibodies delays wound
healing [75]. Application of LL37 resulted in neovascularization and it exerts chemotactic
activity that is mediated by formyl-peptide receptor like-1 (FPRL-1) [76, 77], now referred to as
formyl peptide receptor 2 (FPR2) [78]. Administering LL37 contributes to re-endothelialization
and reduces the extent of neointima formation [79]. LL37 is addressed as Antimicrobial
Immunomodulatory Peptide (AIMOP), and both antimicrobial and immunomodulatory
properties are interwoven. The interaction between LL37, mammalian and microbial systems is
summarized in Figure 1.5. There are numerous complex pathways and receptors involved that
can target different regions of the cells, thereby causing wound healing, lysis, apoptosis,
regulation of other immune responses of mammalian cells, and elimination of the microbial cells
from the host system.
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Figure 1.7 Web of LL37 interactions in vivo showing its potential antimicrobial and immunomodulatory
effects (adapted from Burton MF [70]).
1.3 COMPLEMENT SYSTEM
The complement system plays a pivotal role in innate immunity and it has a major influence on
antibody-mediated immunity. Additionally, it acts as a bridge between the innate and adaptive
immune systems [80]. It is one of the most primitive defence combative systems’ that is
responsible for the clearance of cell debris and the recognition of foreign bodies, exogenous and
endogenous threats [81, 82]. The human complement system consists of over thirty circulatory or
membrane-bound plasma proteins. These proteins participate in different cascades, consisting of
receptors and soluble proteins. They interact with one another and also with other cell receptors
promoting elimination of antigens and immune complexes, thereby regulating the immune
response [83]. The complement system is usually described as consisting of three pathways: 1)
classical, 2) lectin and 3) alternative pathway. Recently a new pathway was implemented into the
complement system called the extrinsic protease pathway as summarised in Figure 1.8 [84, 85].
All the activated pathways converge at  precursor protein C3 and give rise to the cleavage
products C3a, C5a and C5b-9 [86].The components of the complement system are observed in
various inflammatory diseases in mice and human tissues [87].
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Figure 1.8 The complement system after activation by pathogens and how all four pathways combine and
play a role in the elimination of foreign bodies (adapted from Ricklin D. [88]).
1.3.1 COMPLEMENT COMPONENT C5A
Complement component C5a is a polypeptide that is released upon cleavage of C5 by both C5
convertase [80] and proteolytic enzymes, such as kallikrien [89] and thrombin [84]. C5a is a 74
residue pro-inflammatory mediator that acts as a strong chemoattractant towards all myeloid
lineages, increasing vascular permeability and inducing smooth muscle cell contraction [90, 91].
It is the sole complement-derived peptide capable of promoting chemotaxis of granulocytes [92].
The complement anaphylatoxin C5a is cleaved to C5a des Arg., which is the result of rapid
degradation of C5a by serum carboxypeptidase [93]. Cells usually are less sensitive to C5a des
Arg than C5a [94]. These complement anaphylatoxins C5a and C5a des Arg are usually present
at inflammatory sites, increasing permeability of blood vessels and attracting circulating
leukocytes. At last, these leukocytes release their secretory constituents and reactive oxygen
species [95]. C5a is known to play important roles in the pathogenesis of inflammatory diseases
like SLE, rheumatoid arthritis, asthma, psoriasis and sepsis [96]. C5a stimulates the expression
of FcγIII and inhibits the expression of FcγRIIB, thereby playing a regulatory role and enabling
efficient responses to immune complexes [97]. C5a also effects the coagulation pathway by
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promoting the formation of fibrin clots and the up-regulation of CXCL8 and tissue factor [98].
C5a interacts primarily with its two receptors C5aR (CD88) and C5L2 (GPR77). Both receptors
consist of seven transmembrane proteins and belong to a rhodopsin-like family. There are
important differences between those two, even though they share structural similarities [99].
1.3.1.1 Receptors for C5a
a) C5aR (CD88)
C5aR is a G-protein coupled receptor (GPCR), which is expressed on non-immune and immune
cells such as leukocytes (neutrophils, monocytes etc.), endothelial cells, cardiomyocytes and
neuronal stem cells [99]. Signaling of C5aR occurs via the mitogen-activated-protein-kinase
(MAPKs), leading to nuclear factor kappa-light-chain-enhancer of activated B-cells with
cytokine and chemokine production and an increase in intracellular calcium [90, 100]. In
neutrophils, C5aR is present on the membrane [90]. C5a binds with high affinity to C5aR, as
described by a two site binding model for this interaction [101]. The main core of C5a interacts
with acidic residues in the N-terminus of C5aR, where as the transmembrane region interacts
with the C-terminus of C5aR [102, 103]. The activated C5aR receptor is phorphosorylated,
which prevents further binding to G-proteins by promoting binding of arrestins. This binding
initiates internalization of receptors into clathrin-coated pits. After being internalized, the
receptor can either be dephosphorylated and recycled to the plasma membrane or degraded in
lysosomes [104].
b) C5L2 (R77)
The second receptor for C5a is C5L2 [105], which is also a GPCR that is expressed on both non
immune and immune cells, such as neutrophils, macrophages, adipocytes or skin fibroblasts, but
at much lower levels as compared to C5aR [106]. C5L2 is reported to have both anti-
inflammatory and pro-inflammatory responses. There is a significant increase in C5L2
expression in acute infection like sepsis [107]. C5L2 has a similar pattern of tyrosine and acidic
N-terminal residues to C5aR, which have been shown to be a major feature of extracellular
binding of C5a [99]. C5L2 binds with high affinity to C5a and C5a des Arg, leading to the
hypothesis that C5L2 could be the second C5a-binding chemoattractant receptor [108].
Antibodies directed against the N-terminal domain or mutation of tyrosine and acidic residues
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in C5L2 N-terminus significantly inhibit C5a des Arg binding but have small effects on their
interaction with C5a [99].
c) Functions of the receptors of C5a
The functions of C5aR and C5L2 are summarized in Figure 1.9. It has been suggested that
unavailability of C5L2 results in an enhanced inflammatory response, leading to the engagement
of C5a with C5aR and therefore counterbalancing the pro-inflammatory effects of C5aR [100].
C5a is known to interact with C5L2 and trigger release of alarmins (HMGB1) [100, 109].
Chronic inflammation can activate the complement system through various cascades. A number
of complement proteins, which lead to the pathogenesis, are detected in tissue lesions. C5aR is
expressed by most of the cell types present in inflamed tissues and binding of C5a to C5aR
causes a chain of biological effects [110, 111].  There is an abundance of C5L2 in permeabilised
neutrophils, demonstrating that the receptor is expressed intracellularly [112]. C5L2 functions as
an intracellular receptor and is activated only after binding of the ligand to C5aR [112]. C5L2
acts as a positive regulator critical in optimizing and regulating C5a and C3a signaling by
heterodimerising with C5aR or C3aR [113]. The inhibitory activity of C5L2 on C5a/C5a des Arg
receptor makes it a potential target of anti-inflammatory drugs [99]. C5L2 and its role in the
vasculature is unknown, but what is known, is that it functions as a “decoy” receptor, binding
free C5a. C5L2 is hypothesized to compete with C5aR for binding of C5a and thus functioning
as a modulating receptor for C5a [114]. It can also negatively regulate C5aR and has discrete
signaling functions [107, 111, 112]. The mRNA expression of C5aR in apolipoprotein E
knockout mice (Apoe-/-) is relatively high, compared to C5L2 in Apoe-/- mice of all ages,
suggesting that C5a contributes to lesion formation and progression [111]. A previously
examined neurodegeneration model shows varying levels of C5L2, according to the stage of the
disease [115], suggesting a similar trend  in atherosclerosis, which could conclude that C5L2
plays a significant role in advanced atherosclerosis. There is substantial interaction between
signaling pathways present downstream of the complement receptors with the other receptors of
the innate immune system, which results in having varied consequences on inflammatory
responses and diseases [114].
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Figure 1.9 Function of C5a receptors and their enhanced inflammatory immune responses adapted from Ward PA.
[100] ).
1.4COMPLEMENT SYSTEM AND PMN
C5a acts directly on PMN (Figure 1.10), thereby, activating and promoting their chemotaxis. The
complement components, such as anaphylatoxins (C3a and C5a) and membrane attack
complexes stimulate PMN by upregulating the expression of adhesion molecules thus promoting
neutrophil-endothelial reaction. This reaction is a key event in inflammatory processes having
profound effects on both neutrophils and endothelial cells (ECs) [116]. C5a, being a potent
chemotactic factor, elicits major response from PMN. The activated PMN form aggregates and
triggers the immune response. In addition, it generates free radicals like ROS, releases
intracellular proteins, promotes chemotaxis, migration, cytokine release and release of NETs
[117]. The inflammatory changes brought about by PMN and their release of intracellular
granule proteins trigger complex signaling cascades [118]. The changes in neutrophils promote
enhanced adherence to ECs, the release of soluble mediators and the formation of pores on the
endothelium thereby increasing vascular permeability [116]. As a result of that, the process of
extravasation and migration into the interstitial spaces is facilitated and promoted [119].
Neutrophils are also known for complement activation and C5a production and are known to
play a key role in triggering immune responses and inflammation in atherosclerosis [120].
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Uncontrolled production of C5a or upregulation in C5aR is observed in inflammatory diseases,
such as rheumatoid arthritis, dermatitis and fibromyalgia, [98]. Chemoattractants signal GPCRs
such as the chemokine receptors and complement C5a receptors. Upon the activation of these
receptors, neutrophils adhere and migrate to the inflamed tissue releasing inflammatory
mediators in the process and promoting response from other immune cells [121].
Figure 1.10 PMN activation by classical and alternative pathways of complement system, eliciting PMN response
(adapted from Kilgore KS. [117]).
1.5NETS
PMN have traditionally been considered as hallmark of inflammation and they restrict
inflammatory bodies and infection by either phagocytosis, degranulation or a third recently
identified mechanism, the release of NETs, as shown in Figure 1.11 [64]. Upon encountering
pathogens, neutrophils release a mesh-like structure capable of eliminating pathogens. These
web-like traps contain DNA/histones as backbone, peppered with neutrophil granule proteins.
This structure was termed as neutrophil extracellular traps (NETs) [122]. NETs have been
observed in many species; human, mice, fish, chicken, pigs, rabbits, horses, cows, cats,
chinchillas [123-127]. Note worthy in this respect, extracellular traps are also released by mast
cells and eosinophils [128].
A variety of stimulants such as PMA, lipopolysaccharide (LPS) and IL-8 induce PMN to release
extracellular nuclear traps with the ability to kill microbes. Nuclear chromatin-DNA serves as the
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basic backbone of NETs and consists of histones with adherent granule proteins of PMN [129].
The high local concentration of anti-microbial peptides (AMPs) and granule proteins in NETs
eliminate the trapped microbes and pathogens. When microbes or stimulants activate PMN,
NETs are released within 2-3 h [130]. Neutrophils can also release NETs within min of
activation in the presence of LPS and platelets by indirect stimulation of neutrophils [131].
Figure 1.11 The antimicrobial strategies of PMN: phagocytosis, degranulation and NET formation and time
required to activate the respective strategy and the effect on the host. Abbreviations: NE, neutrophils elastase; MPO,
myeloperoxidase; Hs, histones (adapted from Papayannopoulos V. [64]).
The mechanism of NET formation requires active rearrangement of nuclear and granular
components. Upon activation, PMN flatten, turn phagocytic and motile, and form ROS.
Furthermore, the nucleus looses its lobular structure, while chromatin segregation takes place.
After around 2 h of stimulation, the nuclear membrane disintegrates and the nuclear contents mix
heterogeneously with the cytoplasm and granule components. Subsequently, the cell bulges, and
the cell membrane bursts, leading to the release of cell contents in a pathogen-clearing strategy,
referred to as NETosis, as shown in Figure 1.12 [132, 133].
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Figure 1.12 Mechanism of NETs formation: activation with different stimuli lead to ROS formation (1). The nuclear
membrane disintegrates and integrity of granules is lost, (2) The contents of the nucleus mix with the contents of the
cytoplasm, (3) The nuclear and granular integrity is completely lost, and (4) NETs released (adapted from Brinkmann
V. [133]).
The two most important agents in the process of NET formation are ROS and histones ROS is
produced followed by the subsequent release of NE and myeloperoxidase (MPO) from
azurophilic granules of PMN. NE translocates to the nucleus and digests nucleosomal histones,
promoting chromatin decondensation and the release of NETs with NE and MPO sticking to the
extracellular DNA [134]. TLRs, Fc-receptors and other cytokine receptors of PMN are involved
in the activation of protein kinase C (PKC). These receptors play a role in activating NADPH
oxidase, which are responsible for ROS generation. Inhibition of exogenous catalases increases
NETs formation. Patients with granulomatous disease, exhibiting a mutated NADPH oxidase,
produce NETs upon stimulation with hydrogen peroxide.  The latter indicates that ROS
formation is absolutely necessary for formation of NETs [129-131]. Histones are another
important factor for NETs, which was proved by recent studies showing that histone deamination
hampered NET formation [135, 136].
1.5.1 FUNCTIONS OF NETS
NETs contain neutrophil-derived pattern recognition molecules (PRMs) like pentraxin 3 (PTX3),
which are partly localized on their structures [137]. PTX3 interacts with Fcγ receptors and
activates the classical pathway of the complement cascade [137]. Furthermore, PTX3 interacts
with P-selectin during neutrophil recruitment and inflammation, thereby inhibiting neutrophil
extravasation [138]. As a result, NETs aid in producing and recruiting components of the
humoral arm of the innate immune system, by releasing soluble PRMs that enhances
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phagocytosis, regulates inflammation and activates the complement system [137]. Additionally,
NETs act as an emergency trapping mechanism and prevent the spread of pathogens while also
supporting the recruitment of immune cells for triggering inflammation [139]. During systemic
infection caused by Escherichia coli (Ecoli), platelets induce NETs and thereby trigger the
coagulation cascade, leading to intravascular coagulation in liver sinusoids and fibrin deposition
[140]. A broad range of proteins (defensins, cathelicidins, MPO) are present on the NETs with
strong anti-microbial and immunomodulating properties [141]. Additionally, NETs also assist in
protease mediated-effector functions and intracellular signal transduction, leading ultimately to
the activation of the complement system [142]. The activated complement system invokes
monocytes, macrophages, dendritic cells, B-and T-cells for the clearance of apoptotic and
inflamed cells [143]. NETs express autoantibodies against microbial peptides, which are
recognized via interaction between CD32 and transported intp pDCs. Self DNA triggers TLR9
activation and releases IFNα [137]. Consequently, IFNα from the pDCs trigger PMN to release
large amounts of granule proteins resulting in increased formation of NETs [144].
Large amounts of NETs are released by PMN during inflammation and tissue damage. Aberrant
NETs formation and patient’s lack of DNases to degrade NETs might contribute to prolonged
persistence of NETs, tissue damage and autoimmune diseases [145]. The granule proteins and
enzymes present on NETs result in substantial increase of inflammation and promote recruitment
of scavenger cells, contributing to tissue damage [145].
Since NETs are mostly made up of DNA, some pathogens secrete DNases or catalases as a
strategy to degrade NETs, thereby avoiding being trapped in them and also eliminating ROS
formation in the process [64, 146].
1.6ATHEROSCLEROSIS
Cardiovascular disease (CVD), is one of the major causes of deaths worldwide and is a cause of
economic burden on the society [147]. Atherosclerosis is a chronic and progressive inflammation
of the large vessels [148]. It is characterised by the accumulation of inflammatory cells, lipids
and extracellular matrix in the vessel wall that lead to stenosis of arteries [149], called
atherosclerotic plaques. Over time, the plaques grow, erode, rupture and occlude the vessel, as
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shown in Figure 1.13. When the plaques rupture, the pro-thrombic components of the plaque
come into contact with the blood, activate thrombus formation, leading to obstruction in
coronary artery [150]. Depending on the site of injury and obstruction this may lead to
myocardial infarction or stroke [151].
Figure 1.13 Progression of atherosclerosis, from the left to right depicting stages of plaque progression (adapted
from Pepine CJ. [152]).
Recent studies in the field of vascular biology have shown that lesion progression in
atherosclerosis is driven by the influx of inflammatory cells from the blood stream [153].
Atherosclerotic lesions (plaques) develop due to the initiation and activation of dysfunctional
endothelial cells. The leukocytes adhere to the damaged endothelium and increase permeability
of the vessel wall for plasma components such as LDL [150]. The LDL undergoes enzymatic
modifications in the intima and further activates the ECs to express adhesion molecules, resulting
in adhesion and transmigration of neutrophils and monocytes. Monocytes differentiate into
macrophages which phagocytose the modified LDL, following by conversion into foam cells.
This process is an important factor for the formation of fatty streaks, the first stage in
development of atherosclerosis [154]. Fatty streaks progress into atherosclerotic plaques due to
secretion of growth factors, cytokines and chemokines causing further accumulation of
inflammatory cells, smooth muscle cells and matrix proteins [154]. The fatty streaks are
asymptomatic and could progress into mature atheromas or deteriorate with time [155]. Necrosis
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of lipid-laden cells results in the accumulation of cholesterol and the formation of a necrotic core
surrounded by a fibrous cap. The matrix degrading proteases released from the cells in the
plaque, thins the fibrous cap, weakens the plaque and ruptures it. The rupture leads to an
occlusion of the vessel wall due to interaction of lipids from the plaque and tissue factor present
in the blood, leading to thrombus formation and occlusion of the vessel [156], as summarized in
Figure 1.14.
Figure 1.14 Initiation and progression of atherosclerosis, angiogenic factors alter the endothelial function
triggering recruitment of leukocytes and release of cytokines and growth factors. Vascular smooth-muscle cells
(VSMCs) migrate, proliferate and form a fibrous cap with synthesis of matrix proteins. Inflammatory infiltrators thin the
fibrous cap with the release of proteases, weakening the plaque forms thrombus. In advances plaques fibroblasts,
VSMCs with extracellular calcium cause fibrocalcific lesions. a) initiation with endothelial dysfunction; b) progression
into early lesion and accumulation of immune cells; c) Thinning of fibrous cap and plaque rupture leading to thrombus
formation; d) occlusion of the vessel forming advanced lesion (adapted from Dzau, VJ. [157]).
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1.6.1 COMPLEMENT IN ATHEROSCLEROSIS
There is a constant influx of literature implying the role of complement system in
atherosclerosis. The complement system presents an important link between inflammation and
atherosclerosis progression, as shown in Figure 1.15. Atherosclerotic lesions have several
metabolites, triggering the complement system, such as modified LDL, immunoglobulins,
pentraxins, apoptotic cells and cholesterol crystals [158]. The activated complement system
releases anaphylatoxins and its receptors, which are identified in the atherosclerotic plaques. In
normal arteries, no significant complement activation takes place [158-161]. The anaphylatoxins
bind to their receptors the C3a receptor and C5a receptor to act on their target cells. The
complement in atherosclerosis is activated by either classical or alternative pathways but little is
known about  the lectin and extrinsic protease pathways [162]. The deposition of C5b-9 complex
in the lesions co-relates with the extent of the disease, which is present usually deep in the intima
[162]. The immunoglobulin complexes, which are retained in the plaques, form immune
complexes with modified LDL and activate either the classical or alternative pathways [162,
163]. C5a acts as a chemotattractant to recruit monocytes, lymphocytes and mast cells, also
aiding the migration of inflammatory cells into the intima, thereby inducing the expression of
adhesion molecules on endothelial cells [164]. C5a activates the cells to release cytokines and
chemokines. The activated complement system protects by containing infections and eliminating
microorganisms, by either lysis or opsonization. It is also involved in promoting solubilization
by transport transport to RBCs and acting as a waste disposal mechanism. Circulating levels of
complement increases in patients with myocardial infarction and unstable coronary artery disease
[165]. C5a plasma levels are known to predict future cardiovascular events, suggesting that it
could be involved in destabilization of plaques [165]. The complement proteins trigger the
adaptive immune system, also controlling the Fcγ-receptor, activating DCs, B- and T-cells [162,
164].
Experimental animal studies suggest that complement activation may be protective against
development of atherosclerotic lesions by clearing apoptotic cells and debris from atherosclerotic
plaques [166]. Complement C3 deficiency was associated with increased aortic plaque size and
C3-/-/LDLr-/- mice showed unstable phenotype with increased macrophage content [166]. The
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inhibition or blocking of complement C5aR with peptidomimetic C5aR antagonist (C5aRA) or
anti-C5aR mAB, limits neointimial formation after wire injury in Apoe-/- mice. Short term
treatment with C5aRA and anti-C5aR mAB reduced neointimal plaque area, inflammatory cell
recruitment and VCAM-1 expression in carotid arteries [161].
Figure 1.15 Summary of the biological effects of complement activation in athrosclerotic arterial intima,
generating effector molecules; anaphylatoxins (C3a and C5a), opsonins (C4b, C3b,) membrane attack complex C5b-
9 showing cell specific effects in arterial intima (adapted from Oksjoki, R. [167]).
1.6.2 PMN AND LL37 IN ATHEROSCLEROSIS
Infiltrated PMN are seldom observed in atherosclerotic tissues (human and mice) in comparison
with other inflammatory cells [168]. They have  a limited life span in the inflamed tissue, hence
even small numbers of neutrophils detected in tissues reflects considerable extravasation in vivo
[169]. PMN play important roles on virtue of their extravasation, secretion of granules and
secretory vesicles. Furthermore, they are essential for the adhesion of inflammatory cells,
respiratory burst and degradation of extracellular matrix, thereby contributing to the progression
of atherosclerosis [168, 170]. PMN release lipid mediator leukotriene B4 (LTB4) necessary for
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stimulating release of granule proteins, vascular adhesion and, generation of ROS [168]. PMN
release cytokines that recruit and affect functions of SMCs and ECs, thereby contributing to
major pathogenic effects in atherosclerotic plaques [171]. Neutrophils play a prominent causative
role in the early phase of atherosclerosis as shown in Figure 1.15 [172]. A correlation between
PMN count and plaque size has been observed in atherosclerotic lesions and neutropenia reduces
plaque size [172]. PMN numbers increase in patients with unstable angina, myocardial infarction
and other CVDs that pose a high risk factor for atherosclerosis, showing increasing numbers of
neutrophils with severity of the disease [168, 173]. In hyperlipidemia an increase in plasma MPO
levels is seen, but circulating PMN contained less MPO, suggesting granule discharge in the
plasma. Modified LDL, produced in large amounts in the plaques, stimulates PMN adhesion and
transendothelial migration [174, 175]. Degranulation and long exposure to cytoplasmic granules
and modified lipids would enhance inflammation and tissue destruction with the recruitment of
macrophages and monocytes [176].
Granule proteins (LL37, azurocidin) are considerably detected in human plaques [26]. The
activated PMN releases LL37 extracellularly as a consequence of degranulation. Moreover, it
acts as a chemotactic stimulus for monocytes, dendritic cells, macrophages and mast cells to
accumulate at the site of inflammation, as shown in Figure 1.16 [50]. Granule proteins are mostly
found on the luminal side, where they also affect the plaque by changing the morphology of the
plaque. The plaque turns from being stable to vulnerable by weakening of the fibrous plaque
[175, 177]. These proteins modify the LDL in plaque into oxLDL, which are engulfed by
macrophages [178]. Furthermore, LL37 induces mast cell degranulation, promotes
neovascularization and re-epithelization. In addition, it is upregulated as part of the inflammatory
process during atherosclerosis [179]. LL37 plays an important role as regulator of inflammation
on ECs and increases the expression of adhesion molecules and chemokines [179]. It induces
neovascularization and thereby promotes recruitment of leukocytes into the lesion [77, 179].
LL37 coated stents were successful in limiting restenosis [180] Finally, LL37 could potentially
be used as a biomarker, measuring the LL37 activity in circulation as an indication of
atherosclerosis progression.
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Figure 1.16 Potential roles of PMN and its granule protein LL37 in atherosclerosis, Recruitment of activated
PMN on the endothelium triggers release of granule proteins leading to recruitment of monocytes and macrophages.
The macrophages phagocytose modified LDL and turn to foam cells. The extracellular matrix is degraded leading to
weakening of fibrous cap and promoting cap rupture and erosion. Release of LL37 would cause an increase in the
concentration gradient of LL37, induce epithelial cells to produce IL-8 and other chemokines, and would further
enhance recruitment of inflammatory cells, promoting immunomodulatory effects (adapted and modified from
Soehnlein O., Bowdish DM. [26, 181]).
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2 AIMS
The main focus of atherosclerosis research is to decipher the role of the immune system in the
development and progression of atherosclerosis. The major aims of my thesis was to examine the
contribution of complement C5a receptors (C5aR and C5L2) and neutrophils (PMN) in
atherosclerotic lesion progression.
Complement component C5a and its functional receptors are known to play a critical role in
vascular pathology. The pro-inflammatory role of the classical C5aR has been investigated in a
mouse model of restenosis. In this model of restenosis it has been demonstrated that C5aR-
mediated proinflammatory action may occur stage-dependently. However, the expression and
function of the second alternative receptor for C5a, named C5L2 (C5a receptor-like 2), is
completely unexplored. Though some data indicate the co-expression of these two receptors in
certain cells, the co-expression and interaction of these two receptors in the context of
atherosclerosis has not been investigated. PMN were previously not thought to be important in
atherosclerosis. Recent research shows the importance of PMN during early stages of
atherosclerotic lesion progression. Hence, human PMN were predominantly investigated to
evaluate the possibility of cooperative interaction between endogenously expressed C5aR and
C5L2. Additionally, mechanistic insights into neutrophil dependent pro-artherogenic
mechanisms need to be gained. Therefore, my thesis focused on three main aims:
1) The first major aim was to study the C5a receptors in human atherosclerosis and dealt with:
a) Characterization of the stage-dependent expression of the classical proinflammatory
C5aR in human atherogenesis and to elucidate the possibility of a treatment strategy to
block C5aR-expressing cells.
b) Elucidation of the presence of a second alternative receptor C5L2, in human plaques and
to analyze the stage-dependent expression.
c) Analysis of the C5L2-expressing cell types.
d) Analysis of the co-expression of C5aR and C5L2 in human atherogenesis.
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e) Identification of the expression profile of C5aR and C5L2 in PMN following oxLDL
uptake.
2) The second major aim was to analyze the role of PMN in atherosclerosis and dealt with:
a) Detection of NETs in murine and human atherosclerotic specimens (in situ and in vivo).
b) Release of NETs by atherosclerosis-related factors (in vitro).
3) The third major aim was to study the  role of cathelicidins in a mouse model of
atherosclerosis and dealt with:
a) The study of the phenotype of Cramp-/- mice.
b) The role of CRAMP (mouse equivalent to human cathelicidin peptide LL37) in leukocyte
recruitment and atherosclerosis progression.
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3 MATERIALS AND METHODS
3.1 MATERIALS
The general chemicals were bought from Sigma-Aldrich, Merck or Fluka in analytical grade quality.
All solutions were prepared with double distilled water (Heraeus Destamat, Heraeus, Germany),
Millipore water (Milli-Q Plus ultrapure purification, Millipore, MA) or with Aqua ad injectabilia
(Braun, Melsungen, Germany). The general equipment, consumables and kits used are mentioned
below.
3.1.1 GENERAL LAB EQUIPMENT
Autoclave Systec 2540EL, Systec VX-150 (Systec, Wettenberg, Germany)
CCD Camera Hamamatsu 9100-02 EMCCD (Hamamatsu, Hamamatsu, Japan)
Centrifuges Eppendorf 5417C (Eppendorf, Hamburg, Germany), Haereus
Multifuge 3 S-R (Heraeus, Osterode, Germany), Beckman Avanti
J30I (Beckman Coulter, Krefeld, Germany)
Flow cytometer FACSCanto II (BD Biosciences, San Jose, CA, USA)
Fluorescence plate reader Infinite M200 (Tecan, Crailsheim, Germany)
Gel electrophoresis Mini-sub cell GT (Bio-Rad, Hercules, CA, USA)
Laminar flow Herasafe (Heraeus, Hanau, Germany)
Microscope Leica DM-2500 (Leica, Wetzlar, Germany) Olympus IX71 and
BX51 (Olympus Optical, Hamburg, Germany)
Multiphoton LaVision Biotec Trimscope (LaVision Biotec GmbH, Bielefeld,
Germany)
pH-meter InoLab level 1 (WTW, Weilheim, Germany)
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Spectrometer NanoDrop (Peqlab, Erlangen, Germany), GeneQuant
(Amersham/GE Healthcare, Uppsala, Sweden)
Thermocyclers MyCycler (Bio-Rad, Hercules, CA), DNA Engine Opticon
(MJResearch, Hercules, CA, USA), 7900 HT Fast real time PCR
system (Applied biosciences, Germany)
Tissuelyser TissueLyserLT (Qiagen, Hilden, Germany)
Weighing balance Analytical Plus (Ohaus, Pine Brook,NJ, USA), Sartorius CPA 64
(Sartorius, Göttingen, Germany)
3.1.2 GENERAL CONSUMABLES
6, 24, 96 well plates BD, FranklinLakes, USA; Nunc, Roskilde, Denmark
Cell strainer Miltenyi, Bergisch-Gladbach, Germany
Culture slides BD, FranklinLakes, USA
Disposable scalpel Feather Safety Razor Co., Osaka, Japan
Disposable Syringes Terumo, Leuven, Belgium; Braun, Melsungen, Germany; BD,
FranklinLakes, USA
FACS-tubes BD, FranklinLakes, USA
Falcon tubes (15 and 50mL) Greiner Bio-one, Frickenhausen, Germany
Glassware Schott, Mainz, Germany
Microscope slides Thermo Scientific, Braunschweig, Germany
Pipettes (5,10 and 25 mL) Corning, New York, USA
Sterile filter tips Starlab, Ahrensburg, Germany
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3.1.3 GENERAL BUFFERS AND SOLUTIONS
0.01M HCl 1M HCl (stock) diluted 100x in aqua-dest
0.1% Sirius Red solution 0.1g Sirius Red; 100ml saturated picric acid and filter (Make fresh)
0.2%PMA 0.2g of PMA; 100 ml aqua-dest (Make fresh)
Citrate buffer 630 mL Millipore water; 12.6 mL solution A (21.01 g citric acid in
1 L of aqua-dest); 57.4 mL solution B (29.41 g sodium-citrate in 1
L of aqua-dest); 350 µl Tween20
FACS staining buffer 2% mouse serum; 2% rabbit serum (both Sigma-Aldrich, St. Louis,
USA); 2% human serum (Innovative Research, Novi, USA); 4%
bovine serum albumin (BSA) (Serva, Heidelberg, Germany);
dissolved in PBS (PAA, Pasching, Austria)
Hank’s complete 10X HBSS (Invitrogen,Carlsbad, USA) 0.5 M EDTA, 0.6%; 10%
BSA, 6%
Normal medium RPMI 1640 (PAA, Pasching, Austria); 10% fetal calf serum (PAA,
Pasching, Austria)
PMN medium RPMI 1640 (PAA, Pasching, Austria); 10% fetal calf serum (PAA,
Pasching, Austria); 1% gentamycin (Gibco, Invitrogen,Carlsbad,
USA)
RBC Lysis buffer 150 mM NH4Cl; 10 mM KHCO3; 0.1 mM EDTA, pH 8.0
Staining buffer (NETs) 0.3% TritonX; 5% BSA; 3% donkey serum; 0.1% sodium-azide;
made to 100 mL with 0.01 M PBS
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3.1.4 GENERAL KITS
DNA digestion DNase set (Quiagen, Hilden, Germany)
Monocyte isolation Monocyte isolation kit II (MACS, Bergisch Gladbach, Germany)
Real-time PCR Maxima SYBR Green qPCR Master Mix (Fermentas, St. Leon-Rot,
Germany)
Reverse Transcription M-MLV Reverse Transcriptase (Promega, Madison, USA)
RNA isolation RNeasy Mini Kit (Qiagen, Hilden, Germany)
3.1.5 MISCELLANEOUS REAGENTS
Accutase PAA (Pasching, Austria)
Bovine serum albumin Serva (Heidelberg, Germany)
DAPI Vector (Burlingame, CA, USA)
Ethylenediaminetetraacetic acid Bohringer Mannheim (Indianapolis, USA)
Fetal calf serum (FCS) PAA (Pasching, Austria)
Gentamycin Gibco (Darmstadt, Germany)
HBSS Gibco (Darmstadt, Germany)
Hepes Gibco (Darmstadt, Germany)
Human serum Innovative Research (Novi, USA)
Mouse serum Sigma-Aldrich (St. Louis, USA)
Non-essential amino acids (NEAA) PAA (Pasching, Austria)
Paraformaldehyde Sigma-Aldrich (St. Louis, USA)
PBS PAA (Pasching, Austria)
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Penicillin PAA (Pasching, Austria)
Rabbit serum Sigma-Aldrich (St. Louis, USA)
Streptavidin PAA (Pasching, Austria)
Xylazin Medistar (Hannover, Germany)
β-mercapthoethanol Sigma-Aldrich (St. Louis, USA)
3.1.6 MICE
Wild type (wt) C57BL/6, Apolipoprotein E deficient (Apoe-/-) [182, 183] were obtained from the
local animal breeding facility (University Hospital, Aachen Germany). The cathelicidin-related
antimicrobial peptide (CRAMP) knockout mice (Cramp-/-) [184] and mice homozygous for a
knock-in mutation for enhanced green fluorescent protein (EGFP) in the lysozyme M (lys M)
locus Lysmegfp/egfpApoe-/- [185] mice were obtained from the local animal breeding facility.
3.1.7 HUMAN SPECIMENS
Human carotid artery lesions obtained from patients undergoing endarterectomy; with their prior
consent and approved by the institutional review committee. Healthy human carotid artery
specimens were obtained from autopsied individuals in accordance with institutional guidelines.
Samples were fixed in formalin, decalcified and embedded into paraffin blocks. Samples were
sectioned (4 µm thick) throughout the length of the endarterectomy specimen and stained with
Hematoxylin-Eosin (HE), Trichrome and Sirus-Red. The plaques were evaluated for the degree
of fibrosis, plaque inflammation, and intracellular and extracellular lipids. The plaques were
staged 0-VI in conformity with a modified American Heart Association classification system
[186, 187]. Plaques staged I through III were considered as early atherosclerotic lesions and
those staged IV through VI were considered as high-grade pathological lesions. The
classifications of the plaques are as follows:
Stage 0, normal human arteries;
Stage I, type I lesion, an intimal thickening with accumulation of smooth muscle cells only;
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Stage II, type II lesion, an intimal xanthoma with luminal accumulation of foam cells without a
fibrous cap and necrotic core;
Stage III, a pathological intimal thickening with intracellular and incompletely coalesced
extracellular lipids and fibrous cap formation, mild plaque inflammation without necrotic core;
Stage IV, a fibrous cap atheroma with extracellular and intracellular lipids and plaque in-
flammation with necrotic and fatty core, mild plaque inflammation;
Stage V, a fibrous cap atheroma with thick cellular caps overlying a largely necrotic and fatty
core, calcification and intraplaque hemorrhage, moderate plaque inflammation, patterns of
multilayering;
Stage VI, a vulnerable thin fibrous cap atheroma with rupture, hemorrhage and thrombi,
moderate grade of inflammation with infiltration and rare smooth muscle cells an underlying
necrotic core.
3.2 METHODS
3.2.1 MOLECULAR ASSAYS
3.2.1.1 Genotyping
Mice from in-house breeding are genotyped from the tail cuts using protease digestion and
Biosprint15 system (Qiagen, Hilden, Germany) according to the manufacturer’s protocol.
3.2.1.2 RNA isolation
Tissues obtained from human carotid artery lesions are stored in RNA later (Ambion, Texas,
USA). The samples are homogenized in QIAzol (Qiagen, Hilden, Germany) reagent using
Tissuelyser LT (Qiagen, Hilden, Germany) and purified using RNeasy mini kit (Qiagen, Hilden,
Germany) according to manufacturer’s protocol.
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3.2.1.3 Quantification of RNA
RNA concentrations were determined by measuring the absorbance at 260 nm (A260) in a
spectrophotometer. The ratio between 260 nm and 280 nm (A280) determines the purity of the
product. RNA without contaminations has an A260/A280 ratio of 1.8-2.0 at pH 7.0.
3.2.1.4 Reverse transcription
After quantifying RNA, upto 400 ng of total RNA was reverse transcribed into cDNA using
High-Capacity cDNA Reverse Transcription Kit (Applied biosciences, Germany), according to
the manufacturers protocol. The obtained product was dissolved in 20 µL of distilled water to
obtain the working concentration of RNA for Q-PCR.
Sometimes 2 µg of RNA was reverse transcribed using M-MLV RT kit (Promega, Madison, WI,
USA) and random hexamer primers (Fermentas, St. Leon Rot, Germany) for 1 h at 37°C.
5 μl 5x reverse transcription buffer
0.5 μl dNTP mix (20mM each)
1 μl 10μM random hexamer primer
1 μl reverse transcriptase enzyme
upto 2 μg template RNA
H2O to a final volume of 25 μl
From it, like with cDNA obtained from High-Capacity cDNA Reverse Transcription Kit, cDNA
was diluted to a concentration of 10 ng/µL used in Q-PCR reactions.
3.2.1.5 Quantitative PCR
Quantitative PCR (Q-PCR) also called real-time PCR is a technique based on the ability of
fluorescent reporter dye (SYBR Green) to bind to double stranded DNA. With amplification of
the product, the fluorescent intensity of SYBR Green binding to DNA increases over time
associated with the initial concentration. It is majorly used to detect the expression pattern of
different mRNA.
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Around 20-30 ng of cDNA isolated from the human tissues was analyzed by Q-PCR. The house
keeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a reference
gene.
The PCR program was as following-
2 μl cDNA or H2O
13 μl 2x QuantiTect SYBR Green PCR Master Mix
Primer to a final concentration of 1 μM
RNase free water to final volume of 25 μl
Real time-PCR Program:
1. Initial activation 95°C, 15 min
2. Denaturation 94°C, 15 sec
3. Annealing 58°C, 30 sec 42 cycles
4. Extension 72°C, 30 sec
5. Plate read
The relative mRNA expression level of the gene of interest compared to the reference gene was
calculated using the ΔΔct method as described in literature [188].
3.2.2 FLUORESCENT BASED ASSAYS
3.2.2.1 Multiphoton microscopy
The two-photon microscope used was a LaVision Biotec Trimscope multiphoton system
(LaVision Biotec GMBH, Bielefeld, Germany). It uses a single laser beam focused with the help
of Olympus BX61WI microscope with an Olympus 20X NA 0.95; water dipping objective
(Olympus GMBH Hamburg, Germany). The exposed areas were imaged using a pulse laser
(MaiTai HP, Spectra Physics, Mountain View, USA) at 820 nm, which generates the second
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harmonic generation (SHG) helpful in observing the collagen, GFP is signal of neutrophils,
Propidium Iodide (PI) detects presence of extracellular DNA or nuclei of non-viable cells and
auto-fluorescence observed is obtained from the elastic lamina. The detection was with the help
of photomultiplier tubes (PMTs) adjusted to observe the colors of the spectra SHG 400-450 nm;
GFP 500-550 nm; PI 570-610 nm and elastin detected in all the channels. The sections were
imaged on a xy plane and at successive depth in the tissue (z plane ≈ 4 µm). The images were
recorded at an acquisition rate of 5Hz using the Imspector Pro 4.0.43 acquisition software
(LaVision Biotec GMBH). The optical xy-section images obtained without severe motion
artifacts (due to heart- and respiration cycle) and with a comparable z position were further
analysed. The picture quality was improved by resizing the pixel matrix 2 times using a bilinear
scaling technique. 2D Gaussian weighted filtering was utilized to improve overall image quality
by reducing the signal- to- noise ratio- Images were later processed with Image-Pro 3D analyzer
7.0 (Media Cybernetics, Silver Spring, USA).
3.2.2.2 Detection of NETs
Lysmegfp/egfpApoe-/- mice depleted of monocytes to obtain mice with only fluorescent neutrophils.
The mice were injected with TNF (50 ng/ml) and PAF (10 µM) in the scrotum. After 2h of
stimulation the cremaster muscle of mice exteriorized and observed for the formation of NETs
under the multiphoton microscope. Propidium iodide (PI) which stains extracellular DNA was
added locally to the exteriorized muscle. In a similar setup the carotid artery of the mouse was
exteriorized after stimulating with TNF (50ng/ml) and PAF (10µM) i.p. and PI added locally and
i.v. to observe NET formation. To observe the same in atherosclerosis model, the mice were fed
with high fat diet for two weeks, carotid artery is exteriorized and PI added locally and i.v. to
observe the presence of NETs. The exposed areas (cremaster and carotid) were kept moist by
adding saline during the time of experiment.
To detect the presence of NETs in human atherosclerotic lesions, the human specimens were
collected in 1% formaldehyde. The tissue stained overnight in a humid chamber with neutrophil
granule marker, Neutrophil elastase (NE) primary antibody (Abcam, Cambridge, UK) diluted
1:200 from the stock in NETs staining buffer, at room temperature. The excess antibody washed
and stained with anti-mouse IGg Alexafluor antibody, diluted 1:500 from the stock for 2 h at
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room temperature. The excess antibody washed with PBS, counterstained with DAPI and
mounted in 1.5% agarose gel and observed under two-photon microscope.
Human plaques obtained by endarterectomy were embedded in paraffin, 5 µM transverse section
slices obtained. The slices deparaffanized and stained for the neutrophil granule protein marker
neutrophil elastase and the neutrophil surface marker CD177 as mentioned in
immunofluorescence assay. Intracellular and extracellular presence of DNA was identified by
counterstaining with DAPI. CD117 was detected by use of a monoclonal primary antibody (AbD
serotec, Düsseldorf, Germany) and a secondary Cy3-conjugated antibody, while neutrophil
elastase was detected by use of a polyclonal antibody (Abcam, Cambridge, UK) and a FITC-
conjugated antibody. Images were recorded using a fluorescence microscope (Leica DM 2500,
Wetzlar, Germany) and a colour CCD camera (JVC KY-F75U, Friedberg, Germany).
3.2.2.3 Quantification of NETs
The isolated neutrophils from human blood were seeded on to collagen or poly-lysine coated
culture slide at 1x106/mL in 1 mL of PMN medium. Add 1 µL of PMA from the stock of 1
µg/µL and around 30 µg of LDL and oxLDL to stimulate PMN. Incubate for 2 h at 37°C and 5%
CO2, remove the medium and wash with PBS. Add 60µL of 1x micrococcal nuclease mix (New
England Biolabs) and incubate for 20 min at 37°C. Transfer the chamber slide on ice and add 5
mM EDTA to stop the nuclease activity. Transfer 50 µL of the degraded supernatant into a 96
well plate and dilute it 200 times with the addition of PicoGreen reagent (Molecular probes,
Invitrogen) according to manufacturers’ instruction and measure the fluorescence with a plate
reader (Tecan); excitation 492nm and emission 520nm. Non stimulated neutrophils were used as
controls. The release of NETs is calculated-
NETs = PMNtimulated / PMN non-stimulated
3.2.2.4 Flowcytometry
Flowcytometry is used to count, examine and sort microscopic particles (cells) suspended in a
stream of fluid by delivering the individual cells past the measuring point. It is a reliable method
for cell characterization and quantification. The cells on passing the fluorescent light (argon
laser) scatter it basing on the size and granularity. The scattered wave length is recorded as
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forward scatter (size; FSC) and sideward scatter (granularity; SSC) independent of the
fluorescent conjugate.  Fluorescent antibody conjugates are used to stain different cells and to
examine them. The combination of and FSC and SSC is extrapolated and information about the
physical and chemical structure of individual particle can be analyzed. A list of fluorescently
conjugated antibodies is shown in table 3. The protein expression is usually measured by
utilizing fluorescently conjugated antibodies. The principle of flowcytometry can also be utilized
for Fluorescent Activated Cell Sorting (FACS), to sort the desired population of cells.
The cells from blood, spleen, lymph nodes are obtained as single cell suspensions and stained
using combination of antibodies (1:100) in a 50µL of 1:1 mixture of Hank’s complete and FACS
staining buffer on ice for 30 min The cells with contamination of blood are lysed with RBC-lysis
buffer at room temperature, prior to staining with antibodies. Cells are washed and also
suspended in Hank’s complete for analysis in the flowcytometer (FACSCanto II, BD
Biosciences, Franklin Lakes, USA). As control fluorescence minus one (FMO) method was used.
The results are displayed as dot plots showing logarithmic fluorescent intensity plots or graphs
showing changes in fluorescent intensity. The results are evaluated with FlowJo Software
(Treestar, Inc, Ashland, OR, USA).
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Table 2 Fluorescently conjugated antibodies used in flowcytometry
Name mAB Clone Firm
CD45-APC-Cy7 rat anti-mouse 30-F11 BD Pharmingen
CD14-PE-Cy7 rat anti-mouse Sa14-2 BioLegend, San Diego, CA,USA
CD11b-PerCP rat anti-mouse M1/70 BD Pharmingen
CD36 rat anti-mouse No.72-1 eBioscience
MHC-II-APC rat anti-mouse M5/114.15.2 BioLegend
MHC-II-PE rat anti-mouse 2G9 BD Pharmingen
Gr-1-PerCP rat anti-mouse RB6-8C5 BD Pharmingen
F4/80-APC rat anti-mouse A3-1 Serotec, Raleigh, NC, USA
Ly6G-APC rat anti-mouse 1A8 BioLegend
B220-PE-Cy7 rat anti-mouse RA3-6B2 eBioscience
CD40-APC rat anti-mouse 1C10 eBioscience
CD86-PE rat anti-mouse GL1 eBioscience
CD3-PerCP, APC,
FITC
rat anti-mouse 145-2C11 eBioscience
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3.2.2.5 Intracellular CRAMP staining
Intracellular labeling of CRAMP (rabbit anti-mouse CRAMP, provided by R. Gallo) and an
appropriate isotype control (rabbit IgG isotype control, GeneTex) was performed with IC
fixation buffer and permeabilization buffer (both from ebiosciene) according to the
manufacturer`s protocol for staining of cytosolic proteins. Anti-rabbit IgG (ebioscience) served
as fluorescently labeled secondary antibody.
3.2.2.6 Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) is an immunological method to determine and
quantify the amount of antigen present in biological fluids. ELISA performed, was in principle a
sandwich assay. A purified antibody specific for a particular antigen is coated into a microplate.
The samples to be measured along with standards are added to the micro-plates. The plate
washed to remove any unbound antibody and detecting antibody is added. Enzyme-linked
secondary Ab. is added that binds to the detecting antibody. The substrate and later the stop
solution is added and the intensity of the color, measured in plate reader, which is proportional to
the amount of bound antigen. The values are compared to the standard curve obtained by using
the standards.
The cell supernatants were tested for LL37, HNP-1 (both Hycult biotechnology) and MMP-9
assay (Anaspec) according to manufacturer’s instructions. HBP was tested in the laboratory of
Prof. Heiko Herwald (Lund University, Sweden).
3.2.2.7 Immunofluorescence
De-paraffinize (2 x 15 min Xylol, 2 x 5 min 100% ETOH, 1 x 5 min 96% ETOH and 70%
ETOH), wash for 5 min in PBS. Cook the slides in citrate buffer solution for 20 min and allow
the slides to cool to room temperature in the citrate buffer solution. Wash with PBS and circle
around the tissue with a DAKO pen. Immerse in PBS and add blocking solution (6 ml PBS + 1%
BSA (5400 µl PBS + 600 µl 10% BSA) + 3 drops of serum) on the slides, incubate for 30 min in
a dark moist chamber. Shake off the blocking solution from the slides and incubate the slides in
dark moist chamber with primary antibody in the required concentration overnight at 4°C. Wash
with PBS and incubate for 1 h with secondary antibody diluted in the required concentration
from the stock. Wash twice with PBS and mount with DAPI and store at 4°C until photographed.
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Table 2 shows a list of primary antibodies with their corresponding secondary antibodies used in
immuno-fluorescent studies.
Apoptotic nuclei were detected by terminal deoxynucleotidyl nick-end labeling (TUNEL-kit,
Roche).
Tabel 3 Fluorescent antibodies
Primary antibody Secondary antibody
SMA (1:200); mouse anti- human; DAKO anti-mouse-FITC (1:100) or anti-mouse-Cy3
(1:300); Jackson Labs
CD31 PECAM1 (1:50); goat polyclonal
antibody; Santa Cruz Biotechnology
anti goat-Cy3 (1:300); Jackson Labs
Mac-2 (1:400); rat-anti-mouse; CEDARLANE anti-Rat-FITC (1:100) or anti-Rat-Cy3 (1:300);
Jackson Labs
Ly6G (1A8) (1:50) rat-anti-mouse;
BD Pharmingen
anti-Rat-FITC (1:100) or anti-Rat-Cy3 (1:300);
Jackson Labs
CD3 (1:50); rat anti-human (AbD Serotec) anti-Rat-FITC (1:100) or anti-Rat-Cy3 (1:300);
Jackson Labs
CD88 (C5aR) (1:1000); mouse anti-Human;
Abnova
anti-mouse-FITC (1:100) or anti-mouse-Cy3
(1:300); Jackson Labs
R77 (C5L2) (1:200); rabbit anti-human; Genetex anti-rabbit-FITC (1:100) or anti-rabbit-Cy3
(1:300); Jackson Labs
CD68 (1:200); mouse anti- human; DAKO anti-mouse-FITC (1:100) or anti-mouse-Cy3
(1:300); Jackson Labs
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3.2.3 IMMUNOHISTOCHEMISTRY
The tissues (human and mice) are embedded into paraffin blocks and were cut into 5 µM
transverse sections using a microtome and the tissues are stained for various components after
deparaffinizing, by passing twice through xylene solution for 5 min and later passed through
graded ethyl-alcohol (ETOH) solutions (100%, 100%, 96%, 70% and 50%) for 3 min each and
washed by dipping in aqua-dest. and the images are analyzed using Diskus software (Hilgers,
Königswinter).
3.2.4 HISTOPATHOLOGICAL STAINING
3.2.4.1 HE staining
After de-paraffinizing, the tissue are stained with blue nuclear stain Hemathoxyline for 3 min
and washed for 10 min in tap water. After immersing once in aqua-dest, the slide is stained with
red cytoplasmic stain Eosine for 3 min and once again passed through the graded alcohol
solutions (50%, 70%, 96%, 100% and 100%) and then immersed twice in xylene for 5 min The
slides are mounted with resinous medium and photographed under microscope and analyzed by
Diskus software for the phenotype of plaques.
3.2.4.2 Sirius red staining
The tissues are de-paraffinized, rinsed twice for 2 min in aqua-dest. and incubated for 5 min in
0.2% PMA. Excess moisture from the slides is removed and incubated in 0.1% Sirius red
solution for 90 min Excess stain removed by rinsing in 0.01% HCl for 2 min. The slides are
rinsed in aqua-dest and dehydrated by dipping few times in 70% ETOH and twice in 96% and
100% ETOH  followed by twice for two min in xylene. The slides are mounted with resinous
medium and photographed under microscope and analysed for collagen content.
3.2.4.3 Oil-red-O staining
Oil-red-O staining was performed on 5 μm transversal sections through the heart and the aortic
roots or on complete thoracoabdominal aorta opened longitudinally. The tissues were dehydrated
by dipping them 10 times in 60% isopropanol and in 0.5% oil-red-O solution for 30 min. Excess
stain was washed by dipping it 10 times again in 60% isopropanol, washed under running water,
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counter stained for 30s with Mayer’s hamalaun and rinsed under running tap water for 5 min.
The tissues are embedded and photographed and analyzed for the lipid content using Diskus.
3.2.4.4 Alkaline phosphatase staining
The atherosclerotic-plaque tissues were deparaffinised by passing through graded alcohol
solutions. The samples were cooked in citrate buffer solution for 10 min, 600W and allowed to
cool to room temperature in the citrate solution. The slides were incubated for 10 min with
blocking solution (consisting of horse serum, avidin from Vectashield (Vector Laboratories,
Ontario, Canada). Incubated overnight at 4°C with primary antibody (CD88, Abnova or C5L2,
GeneTex) diluted 1:1000 in vectastain blocking solution (Vector Laboratories, Ontario, Canada).
The following morning the excess primary antibody washed and biotinylated secondary antibody
(anti-mouse for CD88, anti-rabbit for C5L2) added on slides and incubated for 30 min at room
temperature and then incubated for another 30 min in alkaline phosphatase solution (2 drops of
reagent A and a drop of reagent B in 10 ml of PBS, prepared 30 min before the actual use),
washed, and incubated for 5-10 min in the Alkaline phosphatase substrate solution (2.5 mL 100
mM Tris-HCL, a drop of reagent 1, a drop of reagent 2 and shortly before using a drop of reagent
3).Washed and counterstained with Mayer’s Hamalaun, washed with aqua-dest and in tap water
till the specimens on the slide turn blue. The tissues are passed through graded alcohols except
Xylol and mounted to be pictured under the microscope.
Similarly plaques were stained for LDL using MDA oxidised primary antibody (abcam) and
continued as mentioned above.
3.2.5 CELL CULTURE
Cell culture was performed under sterile conditions in a laminar flowhood. Cells were
maintained in a CO2-incubator at 37°C and a humidified 5% CO2 atmosphere. Cells were
cultured in growth medium (RPMI 1640) supplemented with 10% (v/v) fetal calf serum (FCS),
penicillin (100 U/mL)/streptomycin (100 μg/mL) (PAA, Pasching, Austria) to avoid
contamination with bacteria. FCS added in the growth medium was incubated at 56°C for 30 min
to inactivate the complement system and stored at -20°C until used.
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All media and solutions used for cell culture were from Gibco if not stated otherwise and
purchased sterile or sterilized through a 0.2 μm filter. Cultured cells were regularly tested to be
mycoplasma free by the VenorGeM Mycoplasma detection kit (Minerva Biolabs, Berlin,
Germany).
3.2.5.1 Neutrophil isolation
Neutrophils isolated as previously described [189], 50 mL of human blood is collected in a
syringe containing 6 mL of mixture obtained by mixing sodium citrate with 6% dextran solution
(1:1). The syringe placed in the plunger for 20-30 min to allow sedimentation. Carefully transfer
the upper straw coloured liquid over 17 ml of Biocoll separating solution in a 50 mL falcon
without mixing the solutions. Centrifuge at 500xg for 30 min at 20-25°C. The blood seperates
into basically 4 distinct bands: plasma, monocytes and basophils, biocoll-paque layer and finally
a pellet of granulocytes and RBCs. Discard the top 3 layers without disturbing the pellet and
centrifuge neutrophils with normal medium for 5 min at 300xg. Add 2 mL of RBC lysis for
approx. 3 min and wash again with normal medium at 300xg for 5 min Wash the cells again and
resuspend them in the desired concentration.
3.2.6 FLOW ADHESION ASSAY
Human aortic endothelial cells (HAoEC) were maintained in the 37°C as described [190].
Human classical and non-classical monocytes were isolated by use of magnetic cell sorting
according to the company’s description (3.1.4). Neutrophils were isolated as described
previously (3.2.4.1). Myeloid cell subsets were then labeled with calcein, resuspended in
endothelial medium and perfused over TNF-activated (20 ng/ml, 12 h) HAoEC at a shear rate of
1.5 dyne/cm2. LL37 was added to endothelial medium 15 min prior to perfusion. Adherent cells
were quantified in six randomly chosen fields.
3.2.7 ANIMAL EXPERIMENTS
All the experiments involving animals were approved by the animal ethical committee of North
Rhine-Westphalia and also according to the guidelines for animal experiments. The animals are
anesthetized by injecting 6-8 mg of Xylazin and 90-120 mg Ketamin and blood drawn via heart
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puncture (anesthetized with isofluran, if animals need to survive (Abbott, Wiesbaden, Germany)
and blood drawn out from the retro-orbital plexus into EDTA tubes (Sarstedt, Nümbrecht,
Germany)). The circulatory system of mice is flushed to remove any coagulating blood with
10mL of PBS and with 10 mL of 4% PFA if the aorta and heart and other organs of the
circulatory system need to be fixed. Aortas were isolated and stored on ice in normal medium.
The aorta was further used for immune-histochemistry (3.2.2.5) or immuno-fluorescence
analysis (3.2.2.4).
3.2.7.1 Mouse models
Mice C57BL/6, Apoe-/-, Cramp-/-, were fed with normal chow or, starting at 8 weeks of age, fed
with atherogenic diet containing 21% fat and 0.15% cholesterol (Altromin, Lage, Germany) for 2
weeks or 4 weeks. The 2 week high fat diet was used for the NETs experiments and for the
Cramp study 4 weeks diet was used.
Hearts and aorta were harvested after in situ perfusion and fixation with 4% PFA followed by
immunohistochemistry and immunofluorescence analysis.
3.2.7.2 Peritonitis
Male wt mice were injected intra-peritoneally with 10 µg Cramp or 50 ng TNF (used as positive
control) in 1 mL of PBS. After 4 h the peritoneal cavity was lavaged with 5 mL of HANK’s
buffer and either continued with FACS analysis or macrophages are cultured. The isolation and
culture of peritoneal MФ is according to the protocol as previously described [191].
3.2.7.3 Peritoneal macrophages
Thioglycollate 3% broth was prepared minimum 6 months before use and autoclaved and stored
under sterile conditions in dark. In the peritoneal cavity of mice, 1 mL of 3% broth injected and
after 4 days by peritonitis (3.2.5.9.2) the cells were collected and by a previously described
method [191], macrophages isolated and cultured basing on their property of adhering to plastic.
3.2.7.4 In vivo depletion of monocytes
Mice are depleted of circulating monocytes by intravenous injection of 200 µL undiluted
chodronate loaded liposomes (Nico van Rooijen, Amsterdam, The Netherlands) as described
previously [192, 193].
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3.2.7.5 In vivo depletion of neutrophils
Neutrophils were depleted by i.p. injection of mAb 1A8 (100 μg/mouse, BioXCell)
3.2.7.6 Lipid detection
Serum levels of cholesterol or triglycerides were assessed by EnzyChromTM Assay Kits
(BioAssay Systems) according to manufacturers’ protocol.
3.2.7.7 Circulating leukocytes
Leukocyte adhesion to the carotid artery was analyzed in Cramp-/-Apoe-/- or Apoe-/- with intact
white blood cell count or with neutropenia. All mice received high fat diet for 4 weeks. The right
jugular vein was canulated with a catheter for antibody and dye injection. The left carotid artery
was exposed as described previously [172]. Thereafter, antibodies to Gr1 (PE, ebioscience) and
CD11b (650NC, ebioscience) were administered to label various leukocyte subsets. Recordings
were made after injection of each antibody. Finally, rhodamine 6G was injected to label all
circulating leukocytes. For luminal detection of CRAMP presented on the endothelium, 50 µl of
Protein G Fluoresbrite® YG Microspheres (Polysciences) were coupled to 50 µg of polyclonal
antibodies to CRAMP (Innovagen, Sweden). Beads and antibodies were reacted for 30 min at
room temperature, washed twice and subsequently injected i.v. into Cramp-/-Apoe-/- or Apoe-/-
with intact white blood cell count or with neutropenia. Antibody/bead complexes were allowed
to circulate for 5 min and immobilized complexes were detected by intravital microscopy.
Intravital microscopy was performed using an Olympus BX51 microscope equipped with a
Hamamatsu 9100-02 EMCCD camera and a 10x saline-immersion objective. Olympus cellr
software was used for image acquisition and analysis.
3.2.8 DATA ILLUSTRATION AND STASTICAL ANALYSIS
Graphs are represented as mean + SD of 3-10 individual experiments, if not stated otherwise.
Student’s t-test with Welch’s correction, 1-way ANOVA with Newman-Keuls multiple
comparisons test, Mann-Whitney, test as appropriate was rendered using GraphPad prism 4
software. Values with P < 0.05 are believed to be statistically significant.
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4 RESULTS
The following section outlines the results obtained and is divided into three parts-
 The first part describes the experiments and results obtained that divulges the roles of, the
complement anaphylatoxin C5a receptors, the classical C5aR (CD88), and the newly
identified receptor C5L2 (C5a receptor-like 2) in human atherosclerosis.
Immunohistochemistry and quantitative PCR were used to report and document the
findings. Since neutrophils were found to be involved in early atherosclerosis [172], the
effect of oxLDL on the expression profile of C5aR and C5L2 in human neutrophils was
analysed in vitro, for the first time.
 In the second part the unique property of neutrophils to release nuclear chromatin with
embedded granule proteins, called Neutrophil Extracellular Traps (NETs) [129] was
examined. Utilizing of intravital two-photon microscopy and immuno-histochemistry, the
presence of NETs in mouse model of atherosclerosis and in human atherosclerotic lesion
was examined for the first time.
 Cathelicidins were identified in atherosclerotic lesions [179]. Thus, in the third part I
investigated their role in a mouse model of atherosclerosis. By using intravital
microscopy, and immunohistochemistry in Apoe-/- mice and Cramp-/-Apoe-/- mice, the
effect of cathelicidin (CRAMP in mouse, LL37 in human), a neutrophil granule protein,
in atherosclerosis was examined.
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4.1EXPRESSION OF C5A RECEPTORS IN DIFFERENT STAGES
OF HUMAN ATHEROSCLEROTIC PLAQUES
The development of atherosclerosis involves prominent inflammatory processes in the vessel
wall. The complement system is involved in every stage of atherosclerosis, from onset till the
development of final stage causing acute thrombotic events [194]. The complement
anaphylatoxins C3a and C5a bind to their respective receptors found on neutrophils,
macrophages and dendritic cells [195]. The cells present in the intima express these receptors
and play an important role in orchestrating the complement activity [165]. C5a is a potent pro-
inflammatory peptide, that interacts with its two receptors C5aR and C5L2. Both these receptors
are present on neutrophils, macrophages and immature-dendritic cells [100]. The potential
function and expression of C5L2 in vasculature is unknown. The focus of the first experimental
part of this thesis was to identify the co-expression of C5L2 with C5aR.
4.1.1 QUANTIFICATION OF C5A RECEPTORS IN DIFFERENT
STAGES OF HUMAN ATHEROSCLEROSIS
To study the expression of the two complement C5a receptors, the human plaques were staged
and characterized as described in materials and methods section 3.1.7. The staged plaques were
stained for C5aR and C5L2 receptors using alkaline phosphatase staining. The data was
quantified by calculating the ratio between the numbers of positive cells (red) to the total number
of cells (blue) in the field of view. The expression levels of C5aR and C5L2 in these staged
plaques were also quantified by using real-time PCR. The expression patterns of C5aR and C5L2
in different stages of atherosclerosis was observed.
As shown in Figure 4.2A, only less than 3 percent of total C5aR-positive cells were detected in
the healthy control tissues (stage 0) and the early stage plaques (stage I). The content of these
cells increased significantly at stage II (type II lesion) compared to the control specimens and
stage I (type I lesion) plaque. All other stages of the plaque had significantly increased
expression of C5aR compared to control and stage I plaques. There were no significant
differences between the different plaque stages from stage II to stage VI. There was marked
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increase in mRNA expression of C5aR in all atherosclerotic stages when compared with their
very low levels in control and stage I (Figure 4.2B) and shows the same tendency like the C5aR-
positive cells (Figure 4.2A). The presence of C5L2-expressing cells and its mRNA expression in
human arteries is shown in Figure 4.2C and 4.2D. In the normal artery (stage 0) and stage I,
staining for C5L2 is essentially negative with the exception of few cells (approximately less than
one percent). C5L2 expressing cells were detected in all pathological stages (stage II- stage VI).
The cell content increases over time and mostly expressed in high-grade pathological lesions like
stage V (Figure 4.2C). This increase was significant compared to stage I and control (stage 0).
In the case of C5aR there were no significant differences between stages II-VI. The mRNA
measurement shows similar tendency like the C5L2-positive cells (Figure 4.2C). On one hand,
there is significant substantial increase in C5aR from stage II and the expression pattern is stable
during different stages of plaque progression. On the other hand, a tendency of gradual increase
in the expression pattern of C5L2 is observed in the positive staining and mRNA quantification
(Figure 4.1C-D).
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Figure 4.1 C5aR and C5L2 are expressed in different stages of human atherosclerotic plaques. Human carotid
artery sections were staged (0 to VI) and stained with antibodies against human-C5aR and -C5L2. The positively
stained cells for C5aR (E) and C5L2 (F) were quantified for total C5aR positive cells (A) and total C5L2 positive cells
(C) by quantifying the staining in 10 view fields and given as a percentage of positively stained cells to the total cell
count in view field. The mRNA expression levels for C5aR (B) and C5L2 (D) in different stages of atherosclerotic
plaques were determined by RT-PCR analysis of total RNA extracted from 47 plaque specimens obtained from
patients and represented as relative fold increase to GAPDH in a logarithmic scale. *control (stage 0) vs. stage I-VI; §
stage I vs. stage II-VI; *§p<0.05; ** §§p<0.01; ***p<0.001.
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4.1.2 LOCALIZATION OF C5AR AND C5L2 IN HUMAN
ATHEROSCLEROTIC PLAQUES
To determine the extent and location of the two complement receptors in human plaques, the
plaque specimens from different stages were stained by using alkaline phosphatase staining with
avidin–biotin complex to detect C5aR and C5L2.
Figure 4.2 Localization and co-expression of C5aR and C5L2 in human atherosclerotic plaques.
Immunohistochemical avidin-biotin-complex (ABC) staining was used on serial sections of human carotid arteries, to
detect C5L2 in co-localization with C5aR. The expression of C5L2 and C5aR, in early plaque specimen (A) and in
high-grade pathological lesion (B). Magnified images of (A and B) are shown in black boxes representing the areas of
interest. Co-expression of both receptors in large lipid-loaded cells is shown as representative images in higher
magnification (C). Cell nuclei were stained by Mayer’s hamalaun. The scale bars are marked in the respective
pictures.
Besides the scattered distribution of C5aR through the arterial plaque, C5aR-expressing cells
were detected in areas of endothelial/luminal site with inflammation, like intimal xanthoma
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(stage II) (Figure 4.2A) and in areas containing a prominent inflammatory influx, such as a late
stage plaque (Figure 4.2B) as detected by serial section immunohistochemistry. Some scattered
C5L2-expressing cells were present through the plaques. However, in contrast to C5aR, these
cells were not expressed in areas of endothelial/luminal site of inflammation as shown in Figure
4.2A. In co-localization with C5aR, C5L2-expressing cells were detected deeper in the lesions
with inflammatory cell accumulation and lipid containing areas (Figure 4.2B). It was surprising
to see that mostly big lipid-loaded foam cells express C5L2 along with C5aR (Figure 4.2C)
prompting me to see what kind of cells express C5L2 and what is the origin of these cells in the
plaque.
4.1.3 CO-EXPRESSION OF BOTH C5A RECEPTORS IN HUMAN
PLAQUE
To detect the co-expression of the two functional receptors of C5a namely C5aR and C5L2, the
human endarterectomy specimens, were stained with fluorescent antibodies targeted against the
receptors of C5aR and C5L2.
Figure 4.3 C5aR and C5L2 are co-expressed in human plaques. Double immunofluorescent staining of the human
tissue stained for C5L2 (green), C5aR (red) and cell nuclei stained by DAPI (blue). Merge is a combined layout of
green and red images, the cell nucleus stained with DAPI (blue), magnification forty times.
From the earlier experiment (4.1.2) it is known that C5L2 is prominently expressed in late stage
plaques (stage IV-VI). These plaques with infiltratory cells, showed the presence of C5L2 and
C5aR prominently near the necrotic core. Figure 4.3 represents double-immunofluorescent
staining for C5L2 (green) and C5aR (red). As observed in the figure not all cells present in the
plaque express either C5aR or C5L2 (Figure 4.3 merge+DAPI). In addition, all the cells that
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express one of the complement C5a receptors do not always express the other. The cells co-
expressing both these receptors are few as seen in Figure 4.3 merge. These experimental data
confirm the combined presence of two functional receptors of C5a in human atherosclerotic
specimens.
4.1.4 CELLULAR EXPRESSION OF C5L2 IN HUMAN PLAQUES
To find out which cell types in the human plaque express C5L2, serial sections of human carotid
endarterectomy specimens were stained by double-immunostaining to detect co-localization for
C5L2 receptors and using antibodies against CD68 to detect macrophages and against CD31 to
detect endothelial cells. Neutrophils were recognized either by fluorescently staining with
CD177 or by alkaline phosphatase staining with MPO. Antibodies against CD3 were used to
detect T-cells and anti-human alpha actin antibodies were used to detect vascular smooth muscle
cells (VSMCs).
C5L2-expressing cells were identified mainly as macrophages (Figure 4.4A), lesser number of
neutrophils (Figure 4.4B), and endothelial cells (Figure 4.4C). CD3-positive T-cells and
VSMCs, lack C5L2 (data not shown). The lack of C5L2 in VSMCs is unexpected.
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Figure 4.4 Cellular expression of C5L2 in human atherosclerotic plaques. Co-localization of C5L2 (green) with
markers for various cell types (red) and nucleus (blue) is shown as photomicrographs. Paraffin-embedded sections
were stained by the double immunofluorescence method for C5L2 - with CD68+ macrophages (A), CD177+
neutrophils (B) and CD31+ endothelial cells (C). L indicates lumen and cell nuclei were counterstained by DAPI, scale
bars 50 µm. Quantification of double-positive cells for C5L2+CD68+ (D), C5L2+MPO+ (E) and C5L2+CD31+ (F)
among C5L2+ cells in view field and given as a percentage. *control (stage 0) vs. stage I-VI; §stage I vs. stage II-VI;
stage II vs. stage IV, VI *§p<0.05; ** §p<0.01.
As shown in Figure 4.4D the C5L2-macrophage (C5L2+CD68+) content increases significantly
in stage II of the plaque and the percentage remains similar from stage III of the plaque. To
measure the neutrophil content the plaques were stained by antibodies against MPO. The
percentage of C5L2-neutrophils (C5L2+MPO+) (Figure 4.4E) had significant increase in stage
IV and stage VI. The endothelial cells expressing C5L2 were significant in stage V of the plaque
(Figure 4.4F).
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4.1.5 C5L2 IS EXPRESSED IN LIPID-LADEN CELLS
To ratify our observation of C5L2-expressing cells being mainly lipid-laden, we performed serial
section immunostaining using anti-oxLDL antibody on frozen plaque tissues along with anti-
C5L2 antibody.
C5L2-expressing cells were positively stained for oxLDL with anti-malondealdehyde (MDA)-
oxidized LDL antibody. These C5L2+oxLDL+ cells were mainly localized around necrotic core
with strong influx of inflammation (Figure 4.5A). These MDA-oxidized LDL cells in the
necrotic core are also positive for C5aR (Figure 4.5B). This proves that C5L2-expressing cells in
complicated plaque stages are lipid-loaded cells, and could be of phagocytic origin. To verify
that lipid-laden cells are also cells of phagocytic origin, these serially sectioned plaques were
stained for MPO, a granule protein released by neutrophils, which would release its granule
contents under phagocytosis or inflammatory conditions. MPO is primarily expressed in the
granule proteins of neutrophils [196]. The oxLDL-stained cells also positively correlate with
MPO (Figure 4.5C). This data shows that C5L2-expressing cells in complicated plaque stages
are lipid-laden phagocytic cells.
Page | 62
Figure 4.5 C5L2 is expressed in oxidized lipid-loaded cells in human plaques. Representative images of
immunohistochemical avidin-biotin-complex staining with alkaline phosphatase enzyme development for oxLDL and
C5L2. Frozen serial sections of human high-grade pathological lesions (n=9) were stained with anti-MDA oxidized
LDL (A, B, C) antibody in co-localization with antibodies against C5L2 (A), C5aR (B) and MPO (C). Areas of interest
are shown as boxed pictures in higher magnification. Specificity is shown by negative control staining (D). Cell nuclei
were counterstained by Mayer’s hamalaun; scale bars 100 µm.
4.1.6 OXLDL STIMULATION CHANGES THE EXPRESSION
PROFILE OF C5L2 AND C5AR IN HUMAN NEUTROPHILS
To confirm our findings on the C5L2-expression in phagocytic lipid-loaded cells from human
plaques, additional in vitro experiments were performed in freshly isolated human neutrophils.
Besides macrophages, neutrophils were the most abundant source of C5L2 and C5aR between
cell types detected in the atherosclerotic plaque.
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Figure 4.6 Effect of the C5a-stimulation and ox-LDL uptake on the expression profile of C5L2 and C5aR in
human neutrophils. Human freshly isolated neutrophils were cultured on fibronectin-coated glass coverslips, and
immunocytochemically stained using fluorescent antibodies against C5aR and C5L2. The nucleus (blue) is stained
with DAPI in all the rows. The first row (A) shows C5L2- and C5aR-co-expression in unstimulated neutrophils.
Second row (B) shows the co-expression in C5a-stimulated (100 nM) neutrophils C5L2 (red), C5aR (green) and co-
expression (merged). In row (C) the receptor expression of DI-labeled oxLDL stimulated (30 µg) neutrophils, oxLDL
(red), C5aR and C5L2 (green), are shown. Scale bars 100 x magnifications. The histograms in row (C) represent
FACS analysis of the expression of C5aR and C5L2 in oxLDL-stimulated neutrophils.
In unstimulated, permeabilized cells (Figure 4.6A), C5aR is markedly expressed on the cell
surface, where as C5L2 is distributed in the cytoplasm. The membrane expression of C5aR is
almost virtually lost and there is an increase in the expression of C5L2 on the surface as well as
in the cytoplasm of neutrophils stimulated with C5a (Figure 4.6B), without any change in the
cell shape and morphology. In neutrophils stimulated with DI-labelled oxLDL (Figure 4.6C),
the expression of C5aR diffuses and expression of C5L2 on the cell surface and in the cytoplasm
increases abundantly. Interestingly, the neutrophils engulfing the labelled oxLDL change their
shape and structure (Figure 4.6C). The oxLDL-stimulated neutrophils were further analyzed
with FACS and surface expression of C5aR and C5L2 could be detected (Figure 4.6C).
Page | 64
4.2PRESENCE OF NEUTROPHIL EXTRACELLULAR TRAPS IN
ATHEROSCLEROSIS
Atherosclerosis is a chronic inflammatory disorder with macrophages and lymphocytes playing
prominent roles. With the recently identified role of neutrophils during early stages of
atherosclerotic lesion formation along with their presence in shoulder regions of atherosclerotic
plaques [172], mechanistic insights into neutrophil-dependent pro-atherogenic mechanisms
remain to be unveiled. Neutrophils have long been viewed as short living cells having an impact
on the innate immune system [137]. Besides their ability to produce reactive oxygen species
neutrophils respond to pathogens by releasing granule proteins and NETs. These enable
neutrophils to cause lethal affects against pathogens [197]. Exposure of host-DNA along with
granule proteins may also orchestrate sterile inflammatory conditions such as atherosclerosis
through activation of antigen presenting cells [74]. NETs have been identified in various disease
models. The focus in this part of the project was to study the presence of NETs in atherosclerosis
mouse model and to detect its presence in human endarterectomy specimens.
4.2.1 MODELS FOR DETECTION OF NETS IN CIRCULATION
To detect the presence of NETs in an acute inflammatory model in mice, Lysmgfp/gfpApoe-/- male
mice were depleted of monocytes as described in methods section 3.2.5.4. These mice now carry
only green fluorescent neutrophils, and were stimulated for 2 h with either TNF (50 ng/ml) or
PAF (10 µM) injected into the scrotum. To the exposed cremaster muscle, propidium iodide was
added topically to detect the presence of extracellular DNA.
Page | 65
Figure 4.7 NETs observed in cremaster muscle of mice. Inflammation was triggered in monocyte-depleted
Lysmegfp/egfpApoe-/- mice by stimulating with TNF (50 ng/mL) for 2 h. After 2 h, the muscle was subjected to staining
with PI topically on the exteriorised muscle. (A) Shows the exposed cremaster muscle pinned for microscopy, (B)
shows magnified view of the cremaster with visible microcirculation, (C) Shows two-photon image of neutrophils
releasing NETs in mouse cremaster muscle. DNA (red), neutrophils (green). The two-photon image in the field area
(C) shows the fluorescent neutrophils covered with a cloud of red PI indicating the release of NETs.
Release of NETs is seen in the microcirculatory model (Figure 4.7C). TNF stimulation initiates
an immune response with recruitment of potentially large number of neutrophils in the cremaster
muscle. Neutrophils roll, adhere and infiltrate into the inflamed tissue caused due to stimulation
with TNF or PAF. The stimulated neutrophils release the DNA extracellularly and the DNA is
stained by propidium iodide which is a membrane impermeable DNA intercalating agent that
fluoresces red. In Figure 4.7C, neutrophils are stained green and DNA is stained red. It is known
that the major constituent of NETs is DNA and neutrophils release NETs in response to
stimulation [129, 198]. Thus the cloud of red observed around neutrophils is confirmed as
released DNA from neutrophils.
After detecting NETs in microcirculation, the next logical step was to observe the same in large
arteries. To attain this goal, Lysmgfp/gfpApoe-/- male mice were depleted for monocytes and the left
carotid artery exteriorised. The exposed artery was stimulated with either TNF (50 ng/ml) or
PAF (10 µM) for 2 h. PI was added on the exposed artery after surgery and before imaging at the
bifurcation.
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Figure 4.8 NETs observed in carotid artery of mice. Inflammation was triggered in monocyte-depleted
Lysmegfp/egfpApoe-/- mice by stimulating with TNF (50 ng/mL) for 2 h. After 2 h, the artery was subjected to staining
with PI topically on the exteriorised muscle. (A) Shows the exposed left carotid artery in mouse pinned for
microscopy, (B) shows magnified view of the left carotid artery, (C) shows two-photon image of neutrophils releasing
NETs in mouse carotid artery. DNA (red), neutrophils (green).The two-photon image in the field area (C) shows the
fluorescent neutrophils covered with a cloud of red PI indicating the release of NETs.
Release of NETs is seen in macrocirculation (Figure 4.8C) as observed in the microcirculatory
model (Figure 4.7C). In Figure 4.8C, neutrophils are stained green and DNA is stained red,
indicating the release of NETs. As observed with the cremaster model, immune response is
observed with recruitment of potentially large number of neutrophils into the carotid.
Neutrophils infiltrate into the inflamed tissue caused due to stimulation with TNF or PAF.
4.2.2 PRESENCE OF NETS IN ATHEROSCLEROSIS
To obtain a relevant information with regard to atherosclerosis, Lysmgfp/gfpApoe-/- mice were fed
with high fat diet and imaged to observe NETs released due to diet-induced
hypercholesterolemia. The mice were fed with atherosclerotic diet for four weeks a time point
when neutrophils were found to be important in atherosclerosis [172]. Following monocyte
depletion by a single injection of chlodronate-filled liposomes, Lysmgfp/gfpApoe-/- mice carry
green fluorescent neutrophils only. The left carotid artery was surgically exposed and imaged at
the site of the bifurcation using a two-photon microscope system. NETs were visualized by
injecting cell impermeable DNA-binding dye (propidium iodide) immediately after surgery and
prior to imaging.
Page | 67
Figure 4.9 Detection of neutrophil extracellular traps in experimental atherosclerosis. (A) Schematic overview
of imaging locations in the murine carotid bifurcation as marked in red and yellow boxes and explanation of visible
structures. (B-D): Single optical xy-sections recorded in vivo utilizing 2-photon microscopic detection of NETs in
monocyte-depleted Lysmegfp/egfpApoe-/- mice after four weeks of high fat diet. DNA was labelled by topical and
intravenous injection of propidium iodide 5 min prior to recording. Neutrophils (green), Collagen (blue), DNA (red) and
scale bars indicate 50 µm.
The chronic inflammation yielded similar results like in the acute inflammatory model to
confirm the release of NETs in high fat diet induced atherosclerosis model. In all mice, adherent
neutrophils were observed at the bifurcation, but only in 57% (n=4) of the HFD-fed
Lysmgfp/gfpApoe-/- mice (group size; n=7) NETs release was observed. The luminally adherent
neutrophils releasing NETs are seen in Figure 4.9B-D. In mice receiving chow diet no
neutrophil adhesion and hence no NET release were observed.
Following the observation of luminal release of NETs in experimental atherosclerosis,
identification of NETs in human atherosclerotic lesions was the next logical step. Plaques
obtained by endarterectomy were used to detect the presence of NETs in humans. The whole
plaques were fixed and stained for the neutrophil granule protein marker neutrophil elastase.
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Intracellular and extracellular DNA was counter stained by DAPI in the tissues. The tissues were
imaged using two-photon microscope system.
Figure 4.10 Detection of neutrophil extracellular traps in human endarterectomy specimens.  (A) Shows the
presence of neutrophil elastase a granule protein marker of neutrophils co-localized with DAPI (DNA marker) in the
Vasa vasorum of the human plaque, (B) 3D reconstruction of the human plaque with Image-Pro 3D analyzer showing
the presence of neutrophil elastase as a long red streak co-localized with DAPI. DNA (blue), Neutrophil-elastase (red)
and Collagen (green).
The images shown in Figure 4.10 establish presence of NETs in human atherosclerotic plaques.
NETs in the whole plaque specimens were usually detected in the vasa vasorum. Since it was
difficult to confirm the presence and to verify the location of NETs in whole tissues, the tissues
were cut into 5 µM sections and stained for neutrophil elastase, along with a neutrophil surface
marker CD177, and DAPI to stain DNA.
A B
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Figure 4.11 Neutrophil extracellular traps are luminally present in human atherosclerotic specimens. (A-E)
Immunohistochemical identification of NETs in human endarterectomy specimens. A) Neutrophil cell surface marker
CD177; B) Staining for DNA; C) Neutrophil ganule protein marker Neutrophil-elastase; D) Overview with merge of A,
B, C, showing the location of NETs; E) Close up of area within the red box in D. CD177 (red), DNA (blue), Neutrophil-
elastase (green). Scale bar indicates 50 µm.
Figure 4.11 confirms that DNA present in the human plaque is released by neutrophils
infiltrating into the tissue. These experiments reconfirm that neutrophils are present in human
plaque. This is the first study to provide evidence for the presence of NETs in an atherosclerotic
environment, both in mice (Figure 4.9) in vivo as well as in human atherosclerosis (Figure
4.11). By the hitherto approach we again could confirm the presence of NETs in luminal location
at sites of atherosclerosis, as in diet induced atherosclerosis mouse model.
4.2.3 ISOLATION AND QUANTIFICATION OF NETS IN VITRO
NETs are generated in vitro as previously described in the literature [198]. Neutrophils are
isolated from blood, seeded on chamber slides and stimulated either with PMA (1 µg/mL) or
DI-oxLDL (30 µg/mL), incubated for 2 h at 37°C to generate NETs.
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Figure 4.12 Neutrophil stimulated with oxLDL releases NETs in vitro. (A) Generation of NETs by stimulation with
PMA viewed under 20x magnification; (B) generation of NETs by stimulating with DI-oxLDL viewed under 100x
magnification. Blue = DNA, Red = oxLDL.
NETs are generated in vitro by stimulating with PMA (Figure 4.12A) which is the basic method
for observing NET release on glass slides. Here for the first time we show that oxLDL stimulated
neutrophils (Figure 4.12B) release NETs. Neutrophils stimulated with PMA release NETs with a
cloudy and diffused appearance [199], which was also observed in our study with oxLDL
stimulated neutrophils.
Neutrophils were isolated and stimulated with PMA (1 µg/mL), LDL (30 µg/mL) or oxLDL (30
µg/mL). The DNA released by various stimulants was quantified according to 3.2.2.2, to
determine the amount of NETs released
Figure 4.13 OxLDL stimulation releases NETs. NETs from isolated human blood in vitro, stimulated with PMA, LDL
and oxLDL release NETs in significant amounts. Data is expressed as mean ±SD, *p<0.05; **p<0.001;***p<0.0001.
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The quantified results show that PMA is a potent stimulant and neutrophils release large amounts
of DNA. Since PMA is not present in the body, we decided to focus on those components which
are present in living beings, keenly focusing on atherosclerosis related compounds. OxLDL,
which contributes significantly in atherosclerotic lesion formation, stimulates neutrophils to
release significant amount of DNA. Peculiarly, LDL does not stimulate PMN to release NETs.
PMA and oxLDL release significant amount of NETs, compared to LDL and control, as shown
in Figure 4.13. With these experiments we substantiate that atherosclerosis related compounds
instigate neutrophils to discharge NETs.
It is reported that neutrophil granule proteins (LL37, NE, Cathepsin G, MMP-9) are co-localized
to NETs [141, 145]. To quantify granule proteins of interest adhering to NETs, DNase was added
to digest the NETs. To assess the concentration of granule proteins bound to NETs. LL37,
MMP9, and HBP were subsequently quantified by ELISA.
Figure 4.14 Neutrophil granule proteins are bound to NETs upon oxLDL stimulation. Neutrophils from human
blood were isolated and these neutrophils were induced to release NETs using PMA, LDL and oxLDL. After gentle
washing, the NET bound proteins were solubilized with DNase. The NET bound proteins were quantified by LL37,
MMP9 and HBP ELISAs. The data shows significant release with PMA and oxLDL. Data is expressed as mean ±SD,
*p<0.05;***p<0.0001.
The granule proteins bound to NETs are quantified by ELISAs as seen in Figure 4.14. PMA is a
potent stimulant to release NETs, and atherosclerosis-related compounds like oxLDL also
stimulate neutrophils to release NETs with almost equal impact. Both PMA and oxLDL trigger
neutrophils to release significant amount of NETs and there by promoting significant release of
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granule proteins adhering to NETs. As seen previously in Figure 4.13, LDL does not stimulate
neutrophils to release NETs. Similarly, we do not see significant release of granule proteins with
LDL stimulation. The picogreen assay and the ELISAs of the digested NETs give conclusive
evidence that NETs are released with oxLDL as with the positive control PMA, and the granule
proteins are present attached to the NETs. Moreover, the amount of NETs released correlate to
the amount of NETs bound granule proteins released. Thus promoting a theory that more the
amount of DNA released from the neutrophils, more is the amount granule proteins bound to
NETs.
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4.3LACK OF NEUTROPHIL-DERIVED CRAMP REDUCES
ATHEROSCLEROSIS IN MICE
Atherosclerosis is a chronic inflammation of the arterial vessel wall, involving complex
interactions between cell types such as macrophages and lymphocytes [200]. Recent studies,
however, have revealed that neutrophils infiltrate atherosclerotic lesions at various time points
[172, 201], and depletion studies provide evidence for a pro-atherogenic role of neutrophils
[172]. However, mechanistic insights into how neutrophils promote early atherosclerotic lesion
formation remain elusive. PMN have long been viewed as short living cells having an impact on
the innate immune system [137]. Neutrophils are known to release their granule content into the
tissue upon activation. Neutrophils contain granules with more than 300 different proteins which
undergo limited exocytosis upon neutrophil extravasation [202]. Some of these proteins are able
to activate and recruit immune cells and have thus been coined alarmins [14]. Cathelicidins
(CRAMP in mouse, LL37 in humans) residing in neutrophil secondary granules were shown to
potently activate and recruit monocytes and macrophages [202, 203] thus fulfilling alarmin
criteria. LL37 has been identified playing a role in pathogenic mechanisms of several chronic
diseases of auto-immune or auto-inflammatory origin [204]. A little is known about cathelicidins
in atherosclerosis though they were identified in lesions [179]. Here we investigate the role of
CRAMP (homologous to LL37) in a mouse model of atherosclerosis.
4.3.1 INADEQUACY OF CRAMP REDUCES ATHEROSCLEROTIC
LESION SIZE
To investigate the role of CRAMP in early atherosclerotic lesion formation, Apoe-/- and Cramp-/-
Apoe-/- mice were fed a high fat diet (HFD) for four weeks and assessed for atherosclerotic lesion
sizes in aortic root sections by staining for lipid and macrophage content. Apoe-/- mice were used
as controls. The mice were sacrificed and the harvested aortas were sectioned into 5 µM thick
aorta sections. The sectioned aortas were analyzed to detect the apoptotic cells in both strains of
mice as described in methods section 3.2.4.3.
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Figure 4.15 Absence of CRAMP reduces atherosclerotic lesion size. Apoe-/- or Cramp-/-Apoe-/- mice were fed a
high fat diet for 4 weeks. (A) Quantification of Oil-Red O stained sections. Representative images are shown below.
(B) DAPI-positive cells enumerating absolute number of infiltrating cells in the aorta. (C) Quantification of Mac2-
positive cells indicating macrophage accumulation. Representative images are displayed underneath. (D)
Quantification of TUNEL staining indicating apoptotic cells. *** indicates p<0.001 between the groups and ** indicates
p<0.01 between the groups. Blue = Nucleus, Green = Mac-2, Red= Lipid.
Lack of CRAMP led to significant reduction in lesion sizes of atherosclerotic plaques in the aorta
(Figure 4.15A). The main feature of aortic root sections from mice lacking CRAMP is reduced
cellularity (Figure 4.15B) and equal decrease in macrophage content (Figure 4.15C). The
decline in macrophage content could be a result of high turn-over and hence the apoptotic
content in these mice was evaluated. No difference was found in the number of TUNEL-positive
cells in the aortic root (Figure 4.15D).
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Mouse serum of Apoe-/- and Cramp-/-Apoe-/- were assessed for serum-cholesterol and
triglycerides (Table 4) after 4 weeks of high fat diet. Counts of circulating leukocyte subsets
were taken either before or after four weeks of HFD (Table 5).
Table 4 Serum lipid levels in Apoe-/- and Cramp-/-Apoe-/- mice
Serum lipids mg/dL
Apoe-/- Cramp-/- Apoe-/-
4 weeks HFD cholesterol 596.9 ± 292.0 626.8 ± 98.02
triglycerides 173.8 ± 79.21 162.3 ± 59.40
Table 5 White blood cell counts in Apoe-/- and Cramp-/-Apoe-/- mice
Blood cells x105 cells/ml
Apoe-/- Cramp-/- Apoe-/-
before HFD monocytes 2.57 ± 0.85 2.85 ± 0.78
- classical 1.25 ± 0.43 1.92 ± 0.57
- non-classical 1.17 ± 0.36 0.94 ± 0.23
neutrophils 5.98 ± 2,60 4.15 ± 1.57
T-cells 12.10 ± 2.60 11.01 ± 2.18
4 weeks HFD monocytes 4.84 ± 0.82 4.36 ± 1.08
- classical 3.65 ± 0.62 2.89 ± 0.51
- non-classical 1.30 ± 0.32 1.20 ± 0.38
neutrophils 9.67 ± 4.76 7.48 ± 2.27
T-cells 6.57 ± 1.56 7.67 ± 2.47
In Table 4 and 5 the mean values and corresponding standard deviation of the mean values of
cholesterol and triglycerides along with the leukocyte count between Apoe-/- and Cramp-/-Apoe-/-
mice at the respective time points are listed. Cholesterol and triglyceride levels did not differ
between Apoe-/- and Cramp-/-Apoe-/- mice (Table 4). Moreover, counts of circulating leukocytes
subsets were not different between the strains either before or after four weeks of HFD (Table
5).
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With the series of above mentioned experiments it became clear that lack of CRAMP
considerably reduced lesion sizes (Figure 4.15A, B) and led to a reduction in macrophage
accumulation (Figure 4.15C). The apoptotic cell content showed no difference, indicating a
regular cell composition of atherosclerotic plaque (Figure 4.15D).
4.3.2 CRAMP IS NEUTROPHIL DERIVED
Cathelicidin is primarily believed to be of neutrophil origin, but some studies have shown it to be
present in macrophages and ECs in human plaque specimens [179]. Thus, to detect the cellular
origin in atherosclerosis, aortas of Apoe-/- and Cramp-/-Apoe-/- mice were enzymatically digested
to obtain single cell suspensions. The cell suspensions were stained with CD45, CD11b, Ly6G,
and F4/80 and the different cell subsets are distinguished based on the gating strategy in Figure
4.16. Along with this strategy, CRAMP was intracellularly stained to determine the origin of
CRAMP in these populations.
Figure 4.16 Schematic overview of analysis of FACS to recognize various cells in the dot plots . The black box
is the cells represented as dot plots and the blue boxes are the gated population.
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Figure 4.17 CRAMP associated with atherosclerotic lesions is neutrophil derived. (A) Intracellular CRAMP
staining in monocytes (SSCloCD45+CD11b+Ly6G-), macrophages (SSChiCD45+ CD11b+F4/80+) and neutrophils
(CD45+CD11b+Ly6G+) of enzymatically digested aortas from Apoe-/- or Cramp-/-Apoe-/- mice having received HFD for
4 weeks. n=5. (B) Immunohistochemical detection of CRAMP in aortic root sections of Apoe-/- (top) or Cramp-/-Apoe-/-
(bottom) mice after 4 weeks of HFD. Stainings were also made by using an isotype control antibody (middle).
Pictures were taken with a 25x objective, inset was taken with a 100x objective. (C) Luminal arrest of G-protein
coupled fluorescent beads conjugated with antibodies to CRAMP in the carotid artery of Cramp-/-Apoe-/- mice, or
Apoe-/- mice with intact white blood cell count or neutropenia. All mice received HFD for four weeks, n=8. *** indicates
p<0.001 compared to mice with intact white blood cell count.
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Intracellular staining of the leukocyte subsets (Figure 4.16) from single cell suspensions of aorta
for CRAMP in Cramp-/-Apoe-/- and Apoe-/- mice reveal that cellular expression of CRAMP in
these cells is confined to neutrophils (Figure 4.17A). Immunohistochemistry of aortic root
sections affirmed that CRAMP is also located in the interstitium of aortic root sections of Apoe-/-
mice receiving HFD (Figure 4.17B) whereas feeding normal chow diet results in markedly
reduced detection of CRAMP (data not shown).
The follow up was to evaluate the possibility of endothelial CRAMP expression, because the
interstitial location of CRAMP is in line with our previous study showing that cathelicidins
interact with extracellular matrix proteins [180]. Apoe-/- mice were injected with microbeads
conjugated to an antibody against CRAMP. The immobilization of conjugated micro beads along
the carotid artery was evident in Apoe-/- mice after four weeks of HFD (Figure 4.17C) In
addition; neutrophil depletion clearly reduced the number of immobilized beads to a level close
to what was found in Cramp-/-Apoe-/- mice (Figure 4.17C). These suggest that CRAMP is
released by activated neutrophils and immobilized on the endothelium a circumstance likely
favored by its cationicity [180].
4.3.3 NEUTROPHIL-DERIVED CATHELICIDIN INDUCES
ADHESION OF MONOCYTES
With no differences in white blood cell counts in Apoe-/- and Cramp-/-Apoe-/- mice as well as
equal numbers in TUNEL-positive cells in the aortic root, reduced accumulation of macrophages
is likely due to impaired recruitment rather than a shift in monocyte/macrophage homeostasis. To
investigate if the reduced macrophage number in Cramp-/-Apoe-/- mice is likely due to impaired
recruitment, the in vivo adhesion of leukocytes in the carotid artery of both strains of mice were
detected by use of intravital fluorescence microscopy.
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Figure 4.18 Neutrophil-derived cathelicidin induces adhesion of inflammatory monocytes. (A) Interactions of
leukocytes with the carotid artery were visualized in Apoe-/- or Cramp-/-Apoe-/- mice fed high fat diet (HFD) for four
weeks by injection of rhodamine (top, labels all circulating leukocytes), an antibody to CD11b (middle, labels myeloid
cells) or Gr1 (bottom, labels neutrophils and inflammatory monocytes), n = 8. (B) Human neutrophils (top), classical
monocytes (middle), or non-classical monocytes were perfused over TNF-activated (20 ng, 12 h) human aortic
endothelial cells and the number of adherent cells was quantified. LL37 (1 µg) was deposited 15 min prior to
perfusion, n = 6. (C) Classical monocytes (left) and human neutrophils (right) were perfused over TNF activated (20
ng, 12 h) human aortic endothelial cells and the number of adherent cells was quantified. LL37 (1 µg) was deposited
15 min prior to perfusion. Leukocytes were pre-treated with the formyl-peptide receptor antagonist boc-PLPLP (1 µM,
30 min) where indicated, n = 6. ** indicates p<0.01 and * indicates p<0.05.
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Cramp-/-Apoe-/- mice exhibit reduced adhesion of rhodamine 6G-labeled leukocytes (Figure
4.18A). Injection of antibodies against Gr1 and CD11b confirm that most of these adherent cells
were myeloid cells of inflammatory nature. The adhesion of inflammatory myeloid leukocytes
was found to be significantly decreased in Cramp-/-Apoe-/- mice compared to Apoe-/- mice
(Figure 4.18A). To thoroughly check if LL37 (cathelicidins) contribute in inducing adhesion of
a particular myeloid subset, isolated classical and non-classical monocytes and isolated
neutrophils were perfused over TNF-activated monolayers of human aortic endothelial cells
(HAoEC). While LL37 induced adhesion of classical monocytes and neutrophils, non-classical
monocytes were not affected (Figure 4.18B). LL37 is known to use formyl-peptide receptors
(FPR) to chemoattract leukocytes [203, 205, 206]. An antagonist to FPR (boc-PLPLP) was used
to investigate if the effect of cathelicidins on the adhesion of leukocytes is specific. Classical
monocytes and neutrophils were isolated and perfused over TNF-activated HAoEC. Leukocytes
were pre-treated with the formyl-peptide receptor antagonist before perfusion. The LL37-
mediated adhesion was expunged by an antagonist to formyl-peptide receptors (FPR) (Figure
4.18C), a class of chemotactic receptors that was previously found to be involved in LL37-
mediated leukocyte recruitment [203, 206].
Thus in vivo adhesions of leukocytes of the carotid artery reveal that reduced adhesion of
rhodamine 6G-labeled leukocyte in Cramp-/-Apoe-/- mice were inflammatory myeloid cells, and
LL37 induced adhesion of classical monocytes and neutrophils and blocking the receptor for
LL37 inversed the scenario.
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5 DISCUSSION
5.1COMPLEMENT RECEPTORS IN ATHEROSCLEROSIS
Here, we exhibit for the first time the expression of both complement C5a receptors in different
stages of human atherosclerotic plaques. Presence of C5L2 receptor is revealed, and C5L2-
receptor expressing cell types in pathological specimens were identified. Both C5a receptors
were expressed in all pathological specimens. Dominant expression of C5aR was observed in the
early stages while the expression of C5L2 increases over time and is prominent in high-grade
pathological lesions. C5L2-positive cells mostly co-express both oxLDL and C5aR. The co-
localization of C5L2 and C5aR in phagocytic cells as neutrophils were analyzed to ascertain the
expression profile of these receptors in the plaque tissue.
Some studies showed the involvement of C5a and receptor C5aR in atherosclerosis and
restenosis. Elevation in C5a plasma levels is seen in patients with advanced atherosclerosis
[207]. C5a was present in human coronary lesions, and its higher levels were associated with
restenosis after balloon angioplasty and late lumen loss of drug eluting stents [207-209]. Levels
of proinflammatory component of C5a in circulating serum increases due to balloon angioplasty
and showed a trend towards significant association with restenosis [208]. Macrophages
stimulated in vitro with C5a showed increased mRNA levels of matrix metalloproteinases
(MMP-1 and MMP-9), indicating the role of locally produced C5a in plaque instabilization
[207]. A previous study reveals the critical role of C5aR in a mouse model of restenosis. Short-
term treatment with human peptidomimetic C5aR antagonist and a C5aR-blocking antibody
limited neointimal hyperplasia, reduced inflammatory cell content and VCAM-1 expression.
Long-term treatment stabilized the plaques, due to increased migration of VSMC, but did not
affect the plaque size [161]. Blocking C5aR improved survival in sepsis, renal allografts and
tublointerstitial fibrosis [161, 210-212], indicating that C5aR has an important role in
maintaining these inflammatory responses.
In the present study, we investigated the stage-dependent expression of C5aR. We found
the presence of C5aR-expressing cells in pathological human specimens, confirming the previous
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study [165]. In all stages of plaque progression, C5aR-positive cells and C5aR mRNA were
detected. The presence of C5aR correlates positively with increasing degree of plaque
complexity. Interestingly, in early atherosclerotic lesions (stage II, III) there were more cells
expressing C5aR than C5L2. This might indicate that inflammatory cells initially recruited in the
damaged vessel, express C5aR. Inhibiting the recruitment of inflammatory C5a-expressing cells
in the early stages of the plaque development by blocking the receptors for C5aR could be a
positive and effective treatment strategy. This would confirm the earlier evidence in mice, that
the blocking recruitment of C5aR-expressing cells in the initial phase of atherosclerosis is
effective [161].
Another important revelation here is the presence of the second alternative receptor C5L2 in
human plaques. C5L2 has been found to be homologues to C5aR [105]. Over the years, several
studies have reported C5L2, as non-signaling decoy receptor and anti-inflammatory molecule in
different disease mechanisms [213]. The functional role of this receptor on vasculature is
unexplored. We show C5L2-expression increases over time without significant differences
between pathological stages. In contrast to C5aR, the C5L2 was rarely determined at the early
stages of atherosclerosis and co-localization studies show C5L2-expressing cells to be
macrophages, neutrophils and ECs. C5L2 is mostly located in the shoulder, lipid-laden areas
around necrotic core and plaque hemorrhage. The intriguing observation of our study is that,
C5L2-expressing cells express C5aR and co-localize with oxLDL in advanced and complicated
plaque stages. C5L2 is an enigmatic receptor that is co-expressed with C5a receptor on many
cells including neutrophils [214], hence can functionally modulate each other regulating the
expression in these cells. Human neutrophils were predominantly investigated to evaluate the
possibility of cooperative interaction between endogenously expressed C5aR and C5L2. Latest
research on human neutrophils reveals C5L2 as an intracellular receptor which consequently is
activated as a result of C5aR activation [112].
Present data shows the presence of more mRNA for C5L2 than C5aR in all atherosclerotic
stages. This could be because of cellular modifications of phagocytic cells through oxLDL,
which would be releasing large amount of intracellular C5L2 in the process. The endogenous
production of C5a would take up all the C5aR available and to cope with the presence of C5a,
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the cells release the internalized C5L2. Earlier findings suggest that, C5L2 is expressed on
neutrophils, macrophages, and in immature-dendritic cells along with C5aR, with significantly
reduced mRNA [105, 113]. Recent observation suggests large amount of intracellularly localized
C5L2 [112]. Additionally, our data contradicts a recent publication, where hyperlipidemic Apoe-/-
mice express lower levels of C5L2 mRNA in different ages of mice. The down-regulation of
C5L2 mRNA occurred in aorta, liver and spleen indicating that this effect is due to the lack of
ApoE in these mice [111]. Further experiments are needed to unravel this mystery.
Previous reports indicate the presence of C5aR at mRNA and protein levels in human and mouse
VSMCs. A specific role of C5aR was identified in the context of arterial neointima formation in
the regulation of VCAM-1 and PAI-1 in VSMCs [161]. PAI-1 is able to inhibit plasminogen
activators and binds to vitronectin or αvβ3 integrins and hence regulates vitronectin receptor
mediated cell adhesion and migration [215]. Over-expression of PAI-1 in ECs inhibits SMC
migration and MMP expression [216]. Therefore, over-expression of PAI-1 by ECs might be
favorable in arterial wall repair and remodeling [216]. VCAM-1 is expressed by intimal SMCs in
aorta and carotids of both men and mice but not found in healthy medial SMCs [217, 218].
VCAM-1 has been characterized as adhesion molecule on endothelial cells that induce response
to inflammatory cytokines and inflammatory cell responses [219]. VCAM-1 is associated with
intimal SMC and mostly found in areas of inflammatory cell infiltrate [217]. Since VSMCs in
plaques expressed C5aR [105, 161], the absence of C5L2 was unforeseen. We conclude that
absence of C5L2 in VSMCs may occur because of its non-phagocytic origin. Blocking C5aR
with anti-C5aR antibody decreases microvascular permeability and adhesion of leukocyte to the
endothelium [220]. Utilizing siRNA to induce gene silencing of C5aR causes inhibition of
complement system and prevents renal ischemia or reperfusion injury [221] and  also can inhibit
C5aR-mediated cultured vascular endothelial injury [222]. In mice C5aR siRNA results in
prevention of plasma leaking of multiple organs [222]. Short-term C5aR antagonist (C5aRA) and
anti-C5aR monoclonal antibody treatment for one week reduced plaque size, leukocyte
recruitment and VCAM-1 expression. Long term treatment reduced inflammatory cell
recruitment, VCAM-1 expression and inducing inhibition of PAI-1 dependent migration of
VSMCs, stabilizing plaques in the neointima without reducing the plaque size [161].
Page | 84
Neutrophils along with macrophages comprise the professional phagocytes. These cells are
endowed the property to engulf and thereby eliminate pathogens and cell debris. Most of our
knowledge of phagocytosis in atherosclerosis is derived from studies on macrophages [223] and
much less is known about neutrophils. The expression analysis of C5L2 in oxLDL-loaded
inflammatory phagocytic cells was never performed. With the recently identified role of
neutrophils in early stage atherosclerotic lesion [172], mechanistic insights into neutrophil-
dependent pro-atherogenic mechanisms remain to be unveiled. The data from the present study
shows that myeloperoxidase (MPO)-expressing cells co-localize with C5L2 in human plaques.
This co-expression of MPO with C5L2 suggests that most of the cells expressed in the plaque are
of phagocytic origin. Since neutrophils are the primary phagocytes that respond to inflammation
or injury in any tissue, we performed additional in vitro experiments on human neutrophils.
There was loss of C5aR and the appearance of C5L2 on the surface after stimulation with C5a,
while both the receptors were detected on the surface after oxLDL stimulation. In my study,
oxLDL is internalized into neutrophils. This internalization of oxLDL could be due to
phagocytosis or taken up by the use of the receptors (scavenger receptors, formyl-peptide
receptors or C5aR) present on neutrophils, inducing the expression of C5L2 on the membrane
but loosing C5aR activity. Plenty of studies reveal that oxLDL is responsible for macrophages
transforming into foam cells [224, 225]. MPO from neutrophils or macrophages modifies LDL in
vitro. In atherosclerosis, these phagocytes could induce oxLDL formation [226]. These
phagocytes later take up the oxLDL in the inflamed tissue [227]. There are more than ten
identified receptors on neutrophils, however, the molecular mechanisms underlying the
recognition of oxLDL and the mechanism of oxLDL uptake by these receptors is unknown [228,
229]. There is data to suggest the role of scavenger receptor CD36 on macrophages in oxLDL
uptake [227, 230]. Similarly, receptor CD36 or other receptors on neutrophils could be
responsible for the uptake, which should be investigated. Whether or not, surface C5aR plays a
role in recognition of oxLDL and thereby leading to the uptake, needs to be examined. Ligand-
binding and flow cytometric analysis reveal negligible C5L2 surface expression in human and
mice neutrophils that interact with C5a on the plasma membrane [112]. Permeabilised
neutrophils reveal abundant C5L2; validating C5L2 is expressed in intracellular compartments.
Unstimulated neutrophils show C5L2 present as granular structures throughout the cytoplasm,
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and in C5a, activated neutrophils both C5L2 and C5aR appear to be translocated into the same
compartments [112]. Mice lacking C5L2 produce neutrophils with an augmented response to
both C5a and C5adesArg, showing 2-3 fold-increase in the influx of neutrophils into the lung,
though the functional role and mechanism of C5L2 regulation remains elusive. Reports unveil
higher levels of tumor necrosis factor-α and interleukin-6 in these mice, compared to wild-type
mice, in a model of pulmonary immune complex injury [214]. A significant reduction in C5L2
was observed in patients suffering from sepsis and C5L2 is thought to act as a scavenging
receptor for C5a/C5adesArg in neutrophils [231]. Other research suggests that reduced number
of peritoneal macrophages were elicited from C5L2-/- mice, which reacted weakly to C5aRA.
Airway hyper-responsiveness and inflammatory cell infiltration was reduced in C5L2-/- mice
[113]. Contrasting data are present which suggest C5L2 to be both positive and negative
modulator of inflammatory responses. Regulation of C5L2 varies depending on the cell type and
level of exposure to anaphylatoxins. Although C5L2 does not appear to use the traditional
mechanisms employed by GPCRs, several studies suggest that C5L2 has the ability to induce
cellular effects [107, 113]. Analyzing cells that express C5L2 primarily and endogenously along
with inflammatory animal models like atherosclerosis will shed light on the role of C5L2.
Identification of the stage-dependent expression of C5aR and C5L2 in human atherosclerosis,
supports being a potential effective treatment in atherosclerosis and restenosis by using C5aR
anatgonist. Moreover, our data deliver first insight into the physiology of C5L2 in the
vasculature in context of human atherosclerosis.
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5.2NETS IN ATHEROSCLEROSIS
Atherosclerosis is the main cause of death, resulting from coronary artery disease, stroke and
peripheral artery occlusive disease. In atherosclerosis the role of monocytes, T-lymphocytes,
mast cells, dendritic cells and platelets have been studied extensively and their role in
atherosclerotic plaque formation, progression and destabilization has been established [26, 156,
175]. Neutrophils which are the most copious of leukocytes in circulation have been ignored in
atherosclerosis. Lately, quite a number of reports point towards significant contributions from
neutrophils in atherosclerosis [232-234].
Neutrophils are most abundant leukocytes in humans and are a first line of defense against
invading pathogens. The most widely used strategy of neutrophils to eliminate pathogens is
phagocytosis. The pathogens devise their own strategy to avoid phagocytosis in vivo [235]. To
efficiently combat and eliminate pathogens, neutrophils have developed degranulation and
recently identified NETs as additional pathogen clearing mechanisms [236]. NETs are sticky
mesh like structures containing a backbone of DNA/histones with granule proteins from the
neutrophils attached to them [122]. NETs were detected in vivo with great difficulty [237]. In
this study we establish for the first time, the presence of NETs in carotid arteries of mice in vivo
in a mouse model of atherosclerosis. In addition, we also confirm the presence of NETs in
atherosclerotic lesions of humans.
Though we establish the presence of NETs in atherosclerosis [238], its functional role in
atherosclerosis remains elusive and needs extensive research to comment on the effect of NETs
on the receptors for lipid metabolism, inflammatory mediator production, vascular homeostasis,
along with various signaling pathways involved in atherosclerosis. Presence of neutrophils-
granule proteins and other antimicrobial peptides on the NETs are reported [141]. In this study
too, we confirm the presence of granule proteins like LL37, MMP9 and HBP on NETs. The
complex of host-derived DNA and granule proteins may trigger inflammatory processes by
activation of antigen-presenting cells such as plasmacytoid dendritic cells [74], eliciting a robust
initiation of innate immune response. Some of the neutrophil granule proteins are directly
chemotactic for mast cells, macrophages, dendritic cells, T-cells and monocytes. The cell-cell
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interactions are capable of producing a number of cytokines that play a crucial role in promoting
inflammatory responses and recruiting inflammatory cells [239]. Nonclassical (human:
CD14dim, mouse: Gr1-) monocytes patrolling along the endothelium may sense host DNA at the
luminal side and be activated [240]. These activated monocytes induce Th17 responses and
promote T-cell proliferation at the site of inflammation in an IL-1β or TNF-α dependent manner
[241]. PMN granule proteins strengthen the monocytes adhesion to the injured endothelium and
instigate sequential extravasation of monocytes [50]. The neutrophil granules also activate
macrophages at the inflammatory sites to phagocytose pathogens and release cytokines. The
activity of regulators of innate immunity like caspase 6 is reduced due to the interaction of
neutrophil granule proteins with macrophages [242].
Both pDCs and resident monocytes have been shown to unleash potent pro-inflammatory
activities [74, 240], e.g. release of type I interferons or tumor necrosis factor respectively. These
pro-inflammatory responses were shown to clearly aggravate atherosclerosis. NETs expose self
molecules extracellularly which leads to autoimmunity, as seen in systemic lupus erythematosus
(SLE), where anti-bodies are formed against chromatin and neutrophil components [243-245]. In
severe sepsis, platelets trigger neutrophils to release NETs [131, 246]. In cystic fibrosis patients,
NETs are present in the lungs, thereby increasing sputum production and reduce function of
lungs by blocking the air ways [247-249]. NETs are known to interact with fibrin strands within
the thrombus and influence thrombus organization and stability [250]. In deep vein thrombosis,
platelets clump with NETs and form severe clots [250]. These NETs-platelet interactions and
subsequent thrombus formation may contribute to the process of atherosclerosis by creating a
luminal environment with locally decreased shear rates, and activation of endothelium [251].
This kind of environment will intensify the recruitment of inflammatory cells into atherosclerotic
lesions. The DNA and proteins in NETs may activate and recruit the contact phase system
thereby aggregating the innate immune response [252]. The presence of NETs and activation of
contact phase system could incite permeability changes, associated with damaged endothelium
[202].
Therefore effective removal of NETs might be required to prevent triggering of immune
response. Removing NETs would mean clearing up of excessive locally bound granule peptides
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on NETs which are present at the sites of inflammation. Some bacteria use Dnase to avoid being
trapped by NETs [253], likewise boosting the local production of Dnase might be beneficial for
effective clearance of NETs. The efficient production of Dnase could be a reason behind not
observing NETs formation in mice fed on normal diet [238]. NETs are important particularly
under conditions where pathogens are not phagocytosed. There must be a balance between the
release and non-release of NETs. Excessive NETs within tissues are likely to have pathogenic
consequences. They could inhibit immune surveillance mechanisms, and inadequate formation of
NETs is likely to have pathogenic consequences by facilitating pathogen survival [254].
In conclusion, our observations are the first to report the presence of NETs in an atherosclerotic
environment in mice in vivo and in human atherosclerosis, which may stimulate further research
on the contribution of NETs in atherogenesis. The latter potentially leads to novel insight in the
interaction between neutrophils and antigen-presenting cells in atherosclerosis. Further
understanding of NETs dependent immune cell activations could provide answers pointing
towards novel strategies that could offer powerful targets to interfere with extravasation of
immune cells and thereby treating inflammatory diseases.
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5.3LL37/ CRAMP IN ATHEROSCLEROSIS
Neutrophils are inimitable components of the innate immune system, which provide the first line
of host defense. Even though finding intact neutrophils in lesions is difficult, numerous
neutrophil granule components have been found in atherosclerotic lesions of humans and mice
[255]. Recent studies indicate the importance of neutrophils during early stages of atherosclerotic
lesion formation [172, 256]. Neutrophils have a large arsenal of granule peptides at their disposal
to eliminate pathogens. Neutrophils upon activation, rapidly release pre-formed granule proteins.
Some of the granule proteins are known to shape vascular inflammatory responses [206]. The
properties of the neutrophil peptides such as defensins and LL37 are divided into either oxidative
or non-oxidative mechanisms [257]. The most important characteristic of these mechanisms are:
firstly, release of granule-associated antimicrobial proteases and peptides and secondly, NADPH
dependent generation of ROS [258]. The anti microbial peptide LL37 is an important member of
the neutrophil arsenal. In this study we identify one role of neutrophil-derived cathelicidin in
mediating neutrophil-dependent monocyte recruitment and macrophage accumulation in early
atherosclerosis. In our study we identify that activated neutrophils secrete cathelicidin which is
immobilized on arterial endothelium due to its cationic nature. There, cathelicidins interact with
formyl-peptide receptors on classical monocytes and promote their firm adhesion. In addition,
cathelicidins are secreted by emigrated neutrophils thus facilitating recruitment of inflammatory
monocytes [259].
LL37 is the only cathelicidin-derived antimicrobial peptide in humans and it shares a homology
with its mouse counterpart CRAMP [260]. Both these peptides are encoded by similar genes,
have similar alpha-helical structures and equal antimicrobicidal activity in the tissues [184].
LL37 affects multiple mechanisms in normal physiology and also is associated with advanced
stages of inflammatory disease such as rheumatoid arthritis [261]. In addition to its antimicrobial
properties cathelicidins act as mitogens for epithelial cells, induce angiogenesis independent of
vascular endothelial growth factor, promote proliferation, cellular migration, inhibit apoptosis
and also serve as a chemoattractant for leukocytes [262, 263].
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The chemotactic activity is mediated by formyl-peptide receptor-like 1 in mice and humans [206,
260]. These receptors are primarily found on phagocyte subsets and it was validated that LL37
attracts neutrophils and monocytes [203, 206]. Besides, cathelicidins indirectly promote
recruitment of effector cells like neutrophils, monocytes, macrophages, T-cells, dendritic cells
through receptor-dependent mechanisms [264, 265]. LL37 acts as a human host defense peptide
that works in synergy with endogenous inflammatory mediators and enhances the effect of
inflammatory effectors that are involved in the complex mechanisms of various pathways [266,
267].
Cathelicidin binds to the bi-products released by pathogens and thereby reduces the capability of
pathogens to stimulate macrophages. This results in decreased production of proinflammatory
cytokine TNFα, which could reduce the development of sepsis in moderate infections [268].
Lower concentrations of LL37 in circulation could supervise the immune response and at higher
concentrations they could function as immune cell promoters in controlling inflammation [268].
LL37 instigates chemokine production and surface expression of chemokine receptors,
synergistically enhances the IL1β-induced production of cytokines (IL6, IL10) and chemokines
such as MCP1, MCP3, and IL8 in monocytes [269] and promotes release of IL1β via P2X(7)
receptors [264]. This observation fits perfectly with a recent study authenticating the decrease in
macrophage content in aortas or neutropenic mice compared to their controls [172]. This finding
could stimulate the idea that neutrophil-derived cathelicidins may enhance monocyte adhesion
and monocyte extravasation into atherosclerotic arteries, thereby standing out as important
facilitator of monocyte/macrophage accumulation during early atherosclerosis.
Alarmins are a group of structurally heterogeneous, endogenous molecules which are rapidly
released upon damage and exert immune cell recruiting and activating properties [12]. Alarmins
are released by cells undergoing non-programmed cell death but not by apoptotic cells [12].
They are released either via specialized secretion systems, or using endoplasmic reticulum-golgi
secretion pathway [270, 271]. Alarmins promptly activate and recruit receptor-expressing cells
of the immune system [272]. Moreover, they could promote reconstruction of the damaged
inflammatory tissue by restoring homeostasis [12].
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Alarmins are reported in atherosclerosis mainly in necrotic tissues [273]. LL37 acts as alarmin
[274, 275], and hence recruits antigen presenting cells to enhance immune responses to eliminate
infections and inflammation. The alarmins that received attention in atherosclerosis are High
Mobility Group Box 1 (HMGB1) protein, S100A8 and S100A9. HMGB1 is released passively
by necrotic and phagocytic cells in response to inflammatory stimulus [276]. Released HMGB1,
is highly pro-inflammatory via interactions with receptors like TLR-2, -4, -9 and receptor for
advanced glycation end products (RAGE) [277]. HMGB1 is involved in opposing events like
maintenance of cell survival in homeostasis and induction of pro-inflammatory cytokines during
inflammation [271]. HMGB1 is expressed by macrophages in fatty streaks and fibro-fatty lesions
and expressed by vascular smooth muscle cells in aortic lesions [278]. HMGB1 acts as a co-
stimulatory factor and along with T-cell receptor aggrandizes proliferation [279]. Reduced
atherosclerotic lesion sizes with lower macrophage numbers as well as reduction in lesional
inflammatory profile were a result of antibody neutralization of HMGB1 [280]. S100A8 and
S100A9 belong to the family of myeloid-related calcium binding proteins (MRPs) involved in
neutrophils migration [281]. S100A8 and S100A9 are expressed by phagocytes and secreted at
sites of inflammation. S100A8 and S100A9 mediate antiproliferative, antimicrobial and
antinociceptive activities [281]. S100A8 and S100A9 is linked to monocyte recruitment by
aiding their migration through endothelium [282], and are potent inducers of neutrophils
chemotaxis and adhesion [281]. S100A8 and S100A9 are viewed as inflammatory but they are
proved to have anti-inflammatory and immune regulatory actions [283, 284]. During
inflammation or infection due to specific oxidative modifications of S100A8 or S100A9 high
levels of ROS and RNS are produced that arrests their chemotactic properties and could limit
leukocyte recruitment in mice and humans [283, 285]. S100A8 and S100A9 effectively scavenge
oxidants, which might represent a compensatory mechanism at inflammatory sites to promote
tissue repair, generating novel anti-inflammatory responses to affect events in the circulation
[285]. Previous studies have shown that lack of S100A8 and S100A9 reduces atherosclerotic
lesion sizes in response to vascular injury [286]. HMGB1, S100A8 and S100A9 are well known
markers of inflammatory conditions such as multiple sclerosis, rheumatoid arthritis, cystic
fibrosis, SLE, atherosclerosis, vasculitis, myocardial infarction [277, 287]. Similarly,
cathelicidins could be applied as biomarker in atherosclerosis
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Cathelicidins act as alarmins and also as endogenous antibiotic that regulates immune responses
by chemoattracting immune cells, such as dendritic cells and monocytes, to the site of
inflammation/ infection [288]. Complementary studies have revealed that cathelicidins play a
part in wound healing and angiogenesis [204]. Cathelicidin is also reported to have a positive
effect by reducing in-stent restenosis [180] It is also observed that NETs that efficiently
eliminate pathogens have LL37 stuck on the DNA [289].
It is proved in this study that the source of cathelicidin LL37 is neutrophils. Hence, neutrophils
play an important role in early atherosclerosis by depositing cathelicidins and regulating
endothelial recovery. The cathelicidins could act through the FPR2 present on monocytes as
shown here, or through the FPR2 axis which promotes re-endothelialization and limits neo-
intima formation [180]. Though the anti inflammatory activity of LL37 in in-stent restenosis and
its proinflammatory activity in atherosclerosis are observed, further studies could clearly unravel
its role in human vasculature.
The conclusion is, alarmins contribute majorly in atherosclerotic lesion formation and
interference with the respective receptors of these molecules may harbour valuable opportunities
for prevention and treatment.
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6 ZUSAMMENFASSUNG
Diese Arbeit beschäftigt sich mit der Rolle von Komplement C5a-Rezeptoren (C5aR und C5L2)
und Neutrophilen in der Pathogenese der Atherosklerose.
Es ist anerkannt, dass die Atherosklerose eine chronische, entzündliche Krankheit ist und in
deren Pathogenese die angeborene und adaptive Immunantwort beteiligt ist. Trotz eines
beträchtlichen medizinischen Fortschrittes bleiben die kardiovaskulären Krankheiten die
häufigste Todesursache weltweit. Das Komplementsystem ist an der Pathogenese der
Atherosklerose sowohl in den frühen Stadien als auch an den thrombotischen Komplikationen
beteiligt. Das Anaphylatoxin C5a ist ein proinflammatorisches Molekül und bindet an seinen 2-
funktionalen Rezeptoren wie C5aR und C5L2. Die Expression und Funktion des neulich
identifizierten C5L2  in der Atherosklerose ist bisher unbekannt. Der erste Teil der Arbeit
fokussiert sich auf die Identifizierung des Expressionsmusters der beiden C5a-Rezeptoren in
verschiedenen Stadien der humanen atherosklerotischen Plaqueentwicklung. Beide C5a-
Rezeptoren sind in allen pathologischen Stadien exprimiert und die Expression korrelierte mit
der Komplexität der Plaques. Ähnliche Tendenz der Expression konnte bei der Messung der
mRNA festgestellt werden. Während C5aR ab dem frühen pathologischen Stadium spontan
ansteigt und hauptsächlich auf der luminalen Seite des Endotheliums exprimiert, erhöht sich die
Expression des C5L2 nur langsam, die stärkste Expression ist erst in den fortgeschrittenen
komplexen Stadien mit hohen entzündlichen Zellinfiltraten deutlich zu sehen. Wesentlicher
Befund dieser Studie ist die Identifizierung der Rolle von OxLDL auf die Expressionsprofile der
zwei C5a-Rezeptoren in Zellen der Gefäßwand. Die OxLDL-positiven Zellen in den
fortgeschrittenen komplexen Stadien exprimieren gleichzeitig die C5aR und C5L2 Rezeptoren,
welche als phagozitierende Zellen identifiziert wurden. Bei in vitro Experimenten mit frisch
isolierten humanen Neutrophilen konnte nachgewiesen werden, dass durch die OxLDL-
Aufnahme von Neutrophilen der intrazellulär-exprimierende C5L2 auf der Oberfläche der
Neutrophilen exprimiert.
Die ECs, T-Lymphozyten, Monozyten und dendritischen Zellen sind im atherosklerotischen
Prozess involviert. Kürzlich wurde festgestellt, dass die Neutrophilen in den frühen Stadien der
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Atherosklerose eine wichtige Rolle spielen.  In dem zweiten und letzten Teil der Arbeit wurde
der mechanistische Einblick in die neutrophil-abhängigen pro-atherosklerotischen Mechanismen,
wie die Ausschüttung von NETs und insbesondere die Rolle vom Granul-Protein LL37 in der
Atherosklerose beschrieben. In den Mausmodellen wurde gezeigt, dass die Zytokin-Stimulation
zur Ausschüttung von NETs in Neutrophilen führt. NETs wurden in Maus- und humanen
Atherosklerose festgestellt. Die Granul-Proteine wie LL37 (bei der Maus als CRAMP genannt)
wurden in NETs festgestellt, insbesondere  nach einer OxLDL-Stimulation in Neutrophilen. Im
letzten Teil der Arbeit wurde die Rolle von Cathelicidin (LL37) in der Atherosklerose mit Hilfe
von Cramp-/- Mäusen untersucht. Das Fehlen des Cathelicidins führte zur Reduktion der
Ablagerung des Lipids in der Aorta und letztendlich zur Reduktion der Plaquegröße mit
verminderter Zellularität. Das Cholesterol- und Triglyceride-Niveau, auch die Anzahl von
zirkulierenden Leukozyten- und apoptotischen Zellen blieben in diesen Mäusen unverändert. In
den Aorten-Einzelzellsuspensionen für CRAMP in Cramp-/-Apoe-/- und Apoe-/- Mäusen wurde
festgestellt, dass die Expression von CRAMP in Neutrophilen begrenzt ist und aktivierte
Neutrophile schütten CRAMP frei und dadurch werden diese Zellen am Endothel immobilisiert.
Die CRAMP-Aktivität ging in neutropenischen Mäusen verloren. In in vivo Adhäsionsversuche
von Leukozyten auf Karotid-Arterien zeigte sich, dass die LL37-induzierte Adhäsion von
klassischen Monozyten und Neutrophilen und die Blockade von FPR (formyl-peptide receptors)
mit dem Antagonist zu reduzierten Adhäsion von klassischen Monozyten und Neutrophilen
führten.
Zusammenfassend konnte festgestellt werden, dass OxLDL die Neutrophilen stimulieren. Die
endogen produzierte C5a bindet an die Oberflächen-exprimierenden C5aR, durch welche die
C5aR-exprimierenden Zellen in die Gefäßwand rekrutiert werden. Die OxLDL-Aufnahme
induziert die Oberflächenexpression von C5L2 in Laufe der Plaqueentwicklung an der
Gefäßwand. Erhöhtes OxLDL-Vorhandensein stimuliert die Neutrophilen zur Degranulation und
zur Ausschüttung von LL37 oder führt zur Freisetzung von NETs durch NETosis. Dieses
Vorhandensein von NETs und Granul-Proteinen erhöht die entzündliche Zellreaktion, welche zur
Rekrutierung von anderen Immunzellen für das Abräumen der atherosklerose-abhängigen
Produkte steigert. Dieses führt zur Bildung der Läsionen und letztendlich resultieren hieraus die
fortgeschrittenen Stadien der Atherosklerose.
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7 SUMMARY
This study focuses on understanding the role of complement C5a receptors (C5aR and C5L2),
release of neutrophil extracellular traps (NETs) and the role of neutrophil granule protein
(CRAMP in mouse) in atherosclerosis.
Atherosclerosis is agreed to be a chronic inflammatory disease of the arterial vessel wall
involving both innate and adaptive immunity. Despite considerable progress in the field of
medicine, cardiovascular diseases are a major cause of death world-wide. The complement
system is involved in every stage of atherosclerosis, from the onset till the development of acute
thrombotic events. C5a anaphylatoxin interacts with its two functional receptors C5aR and
C5L2. Receptor C5L2 has recently been identified and its role in atherosclerosis is unknown.
C5aR was detected at every stage of atherosclerotic plaque with its receptor expression
increasing with increasing complexity of the plaque. The pattern observed was similar with
mRNA and it correlates with the receptor expression. The C5L2 receptor expression increased
substantially in the late stages of atherosclerosis and then there is a gradual increase in its protein
levels. The present study reveals that C5aR is expressed initially on the luminal side of the
atherosclerotic vessel and C5L2 is expressed in the areas of inflammatory cell infiltrates. Also,
the cells that co-express both the receptors (C5aR and C5L2) and positive for oxLDL are
phagocytic in origin. Neutrophils are the first phagocytic cells that reach the injured tissue.
Neutrophils on engulfing oxLDL have increased expression of C5L2. Following this, internally
present C5L2 on neutrophils and is expressed on their surface.
Neutrophils have been identified recently to be very important in early atherosclerosis. The
mechanistic insight into neutrophil-dependent pro-atherogenic mechanism like release of NETs
in atherosclerosis is unveiled in the second part of this thesis. Cytokine stimulation in murine
models showed release of NETs from the neutrophils. NETs were luminally present in murine
and human atherosclerosis. Atherosclerosis related compound such as oxLDL stimulates
neutrophils to release NETs along with granule proteins, such as LL37 (CRAMP in mouse),
bound to the released NETs.
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In the final part of the project the role of cathelicidin (LL37) in atherosclerosis was explored.
Lack of cathelicidin reduced the accumulation of lipids in the aorta and reduced the lesion sizes
with decrease in cellularity. Compared to the control (Apoe-/-), the knockout (Cramp-/-Apoe-/-)
mice showed no difference in cholesterol triglyceride levels, circulating leukocyte count and
apoptotic cell count. Data from single cell suspensions of aorta for CRAMP in Cramp-/-Apoe-/-
and Apoe-/- mice reveal that cellular expression of CRAMP is confined to neutrophils and the
activated neutrophils release CRAMP and immobilize on the endothelium. In vivo adhesion of
leukocytes of the carotid artery reveals that LL37 induced adhesion of classical monocytes and
neutrophils and blocking the formyl-peptide receptors with an antagonist significantly reduced
the adhesion of classical monocytes and neutrophils.
Thus summarizing the studies of this thesis-
OxLDL stimulates neutrophils leading to the endogenous production of C5a. C5a then binds to
C5aR expressed on the membrane of neutrophils. This C5a-C5aR complex exteriorizes the
internally present C5L2. Moreover, increase of oxLDL stimulates the neutrophils to releases
NETs via NETosis with LL37 adhering to them. The presence of NETs and granule proteins
increase the inflammatory cell environment and recruit other immune cells, aiding in the
progression of atherosclerosis and resulting in advanced stage plaques.
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